Profile Image

Professor Adam McCluskey

Professor

School of Environmental and Life Sciences (Chemistry)

Driving the Therapeutic Drug Revolution

Professor Adam McCluskey has been a driving force behind the establishment of the Centre for Kinomics, a world-first research facility. 

Professor Adam McCluskey 

McCluskey has established the Centre in collaboration with respected neurobiologist Professor Phil Robinson, of the Children's Medical Research Institute (CMRI) at Westmead.

The Centre is named for a biological process called phosphorylation that is mediated by kinases, hence 'kinomics', and which controls the activation of many signalling and enzymatic proteins. 

The Centre, which has laboratories at the University of Newcastle and CMRI, has been funded by a $1 million prize from the Ramaciotti Foundation and a $3.1 million grant from the Australian Cancer Research Foundation for the study of protein kinases and the drugs that target them. 

The Centre's focus is designing next­ generation drugs for epilepsy, cancer and neuropathic pain. So far the focus has been epilepsy, a disorder where one in three sufferers gain no relief from existing treatments. The goal is creating drugs that do not have the often­ debilitating side effects. 

The emerging field revolves around the 518 protein kinases in the body, which are the key signalling proteins behind biological functions. If they malfunction then the body malfunctions. 

Pharmaceutical companies invest billions of dollars in research to develop kinase inhibitors. 

"It's a crude analogy," says McCluskey, "but in drug design there is the lock and the key. You either want to lock or unlock the protein action and the drug is the key that will enable you to do that." 

Using unique equipment costing hundreds of thousands of dollars, the researchers are able to quickly pinpoint the undesirable elements of existing therapeutic drugs. 

"We can identify the range of proteins a drug interacts with and look out for red flags," explains McCluskey, a chemist. "There are some proteins you would never want a drug to touch because of the serious, even deadly, side effects." 

The Centre is extending a 2007 discovery by a private German drug company that involves a new technique for analysing interactions between kinase inhibitors

and hundreds of proteins at a time. The technology is known as Kinobeads and it fast tracks what has been until now a time-consuming process. 

Mass spectrometry determines what proteins have been singled out by the Kinobeads, indicating which kinases have remained bound to the drug in question. The process would normally take at least six months but the Centre's cutting-edge technology will reduce it to a few days.

There are 23 research groups around the world waiting for the Centre to produce its first batch of beads. This technology gives us the ability to rapidly enhance our potential to test and manufacture pharmaceuticals that will benefit many individuals suffering from a range of disorders. 

Professor McCluskey's research is conducted in collaboration with the Hunter Medical Research Institute's (HMRI) Cancer Research Program. His research is supported by grants from HMRI. 

Visit the Priority Research Centre for Chemical Biology

Professor Adam McCluskey

Driving the Therapeutic Drug Revolution

Professor Adam McCluskey has been the driving force behind the establishment of the Centre for Kinomics, a world-first research facility in collaboration with r

Read more

Career Summary

Biography

I obtained my BSc (Hons) and PhD in organic chemistry from the University of Strathclyde in Scotland. At the completion of my studies I took up a postdoctoral position at the University of Queensland in the area of reactive intermediates chemistry (spectroscopy at -261 ºC). After a 2 year stay, I changed research direction working alongside Professor Ron Quinn at Griffith University as a synthetic medicinal chemist. It was here I developed an interest in medicinal chemistry and teaching. In December 1995 I was fortunate to secured a position as lecturer in organic chemistry at the University of Newcastle. My team (the ones who do all the work) is responsible for >125 research publications and we have secured ~$25M in research funding since my arrival in Newcastle.

Research Expertise

Medicinal Chemistry; * Inhibition of Protein Phosphatases as a therapeutic Strategy * Inhibition of Dynamin GTPase * Prevention of Pre-term delivery in Humans: Agonists & antagonists of Corticotrophin Releasing Hormone (CRH) Green Chemistry; Overarching Interest is in the application of organic chemistry strategies in the development of new therapeutic agents (Organic and Medicinal Chemistry). Additionally, given environmental and public concerns relating to Chemistry we are driven by a desire to develop Green Chemistry approaches in our organic and medicinal chemistry targets. Emphasis is placed on solvent free reactions, atom efficiency, replacement of volatile organic solvents with environmentally friendly equivalents (ionic liquids), and evaluation of the most efficient synthetic routes to the desired end-points. My group's primary interests are in developing novel compounds with the ability to inhibit a number of signal transduction pathways. The potential outcomes of our research include (but are not limited to) the development of new synthetic methodologies; the development of new drugs & the development of new tools for dissecting signal transduction pathways.

Collaborations
I am a teaching and research academic who believes that nurturing students and introducing to a positive research experience is one of the pillars of teaching at the University of Newcastle. My research can be classified as either medicinal chemistry or chemical biology. I am known for the development of elegant approaches to highly focused compound libraries of biologically active compound. My team has established considerable corporate knowledge in the area of clathrin mediated endocytosis and its implications in neurological diseases, eg epilepsy. This led to the establishment of the dynamin modulators platform of which I am team leader (chemistry). This team interacts with, and supplies the only known endocytosis inhibitors to research teams worldwide (UK, USA, Germany, Denmark etc). I am also an integral component of the development of new anti-epileptic drugs alongside the National Institute of Health, National Institute of Neurological Disorders and Stroke (Bethesda USA). I head the chemistry component of the Australian Cancer Research Foundation (supported by Ramaciotti) Centre for Kinomics (CFK), a new approach for direct profiling of cellular kinases, a multi-million dollar initiative providing a unique service to multiple research teams throughout Australia. Kinases are the cancer drug target of the 21st century. The CFK offers a unique opportunity to profile biological probes (drugs) and cellular kinases to identify new therapeutic targets, new uses for old drugs and rapid IC50 determination of individual compounds against the entire cellular kinome (cellular complement of protein kinases). The CFK at the University of Newcastle has established one of the first fully equipped flow chemistry laboratories in Australia comprising the ThalesNano H- and X-cube, the Syrris FRX and Syrris Africa work stations, and the VapourTech 4 pump -70 ºC unit. This facility is purpose built for the rapid optimisation of medicinal chemistry pathways and will significantly accelerate the initial optimisation phase of the UoN chemistry component of the multiple drug development pipelines initiated. I am also director of the University of Newcastle Priority Research Centre for Chemical Biology.


Qualifications

  • PhD, University of Strathclyde
  • Bachelor of Science (Honours), University of Strathclyde

Keywords

  • Anti-cancer agents
  • Anti-parastic agents
  • Chemical Biology
  • Clathrin Inhibitors
  • Drug Design and Discovery
  • Dynamin GTPase
  • Flow Chemistry
  • Organic Chemistry
  • Protein Phosphatase Inhibitors

Fields of Research

CodeDescriptionPercentage
111599Pharmacology and Pharmaceutical Sciences not elsewhere classified70
030499Medicinal and Biomolecular Chemistry not elsewhere classified30

Professional Experience

UON Appointment

DatesTitleOrganisation / Department
1/01/2014 - ProfessorUniversity of Newcastle
School of Environmental and Life Sciences
Australia
10/02/2006 - 21/11/2006LecturerUniversity of Newcastle
Centre for Teaching and Learning
Australia

Academic appointment

DatesTitleOrganisation / Department
1/01/2010 - Honorary Scientist
Chemical Biology
The University of Sydney
Children's Medical Research Institute
Australia
1/12/1995 - Associate Professor in ChemistryUniversity of Newcastle
Faculty of Science and Information Technology
Australia

Awards

Recognition

YearAward
2005Vice Chancellors Award for Teaching Excellence, Science & IT
University of Newcastle
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Chapter (3 outputs)

YearCitationAltmetricsLink
2015Scarlett CJ, Vuong QV, McCluskey A, Bowyer MC, 'Pancreatic Cancer Drugs: Case Studies in Synthesis and Production', Plant Bioactive Compounds for Pancreatic Cancer Prevention and Treatment, Nova Science Publishers , Inc., New York 145-193 (2015)
Co-authorsMichael Bowyer, C Scarlett, Vanquan Vuong
2011Booker KM, Holdsworth CI, Bowyer MC, McCluskey A, 'Ionic liquids as porogens in the synthesis of molecularly imprinted polymers', Applications of Ionic Liquids in Science and Technology, Intech, Croatia 197-212 (2011) [B1]
DOI10.5772/21725
Co-authorsMichael Bowyer, Clovia Holdsworth
2002McCluskey A, Lawrance GA, Leitch SK, Owen MP, Hamilton IC, 'Ionic liquids and metal ions: from green chemistry to ore refining', Ionic Liquids: Industrial applications to green chemistry, American Chemical Society, Washington DC, USA 199-214 (2002) [B1]
CitationsScopus - 4Web of Science - 8
Co-authorsGeoffrey Lawrance

Journal article (168 outputs)

YearCitationAltmetricsLink
2015Jackson J, Papadopulos A, Meunier FA, McCluskey A, Robinson PJ, Keating DJ, 'Small molecules demonstrate the role of dynamin as a bi-directional regulator of the exocytosis fusion pore and vesicle release.', Mol Psychiatry, 20 810-819 (2015)
DOI10.1038/mp.2015.56Author URL
2015Cai Y, Postnikova EN, Bernbaum JG, Yu S, Mazur S, Deiuliis NM, et al., 'Simian Hemorrhagic Fever Virus Cell Entry Is Dependent on CD163 and Uses a Clathrin-Mediated Endocytosis-Like Pathway', JOURNAL OF VIROLOGY, 89 844-856 (2015)
DOI10.1128/JVI.02697-14Author URL
CitationsScopus - 1Web of Science - 1
2015Lees JG, Gorgani NN, Ammit AJ, McCluskey A, Robinson PJ, O'Neill GM, 'Role of dynamin in elongated cell migration in a 3D matrix', Biochimica et Biophysica Acta - Molecular Cell Research, 1853 611-618 (2015)

The use of 3-dimensional (3D) collagen gels has yielded new insights into the migratory behaviour of cancer cells. While the large GTPase dynamin has emerged as an important regulator of cancer cell migration and invasion under 2D conditions, its role in 3D migration is unclear. We have used a potent dynamin modulator, a bis-tyrphostin derivative, Ryngo® 1-23, to investigate the role of dynamin in 3D migration in 3 different cell lines. The compound specifically inhibits persistent, elongated 3D migration in U87MG and SMA-560 cells. Treated U87MG cells adopt a rounded morphology that is not due to apoptosis, loss of matrix metalloprotease activity or inhibition of clathrin-mediated endocytosis. Given that Ryngo 1-23 is known to regulate dynamin oligomerisation and actin dynamics at the leading edge, we analysed actin filament distribution. Ryngo 1-23 induced a switch in actin filament organization in 3D cultures resulting in the generation of multiple short actin-rich microspikes. Correlated with the change in actin filament distribution, cells displayed reduced collagen gel contraction. Since acto-myosin force transmission to the extra-cellular matrix underpins persistent, elongated migration, our results suggest that Ryngo 1-23 modulates this process in 3D migration via dynamin-mediated regulation of acto-myosin force transmission to the extra-cellular matrix.

DOI10.1016/j.bbamcr.2014.12.008
2015Daniel JA, Chau N, Abdel-Hamid MK, Hu L, von Kleist L, Whiting A, et al., 'Phenothiazine-derived antipsychotic drugs inhibit dynamin and clathrin-mediated endocytosis', Traffic, (2015)

Chlorpromazine is a phenothiazine-derived antipsychotic drug (APD) that inhibits clathrin-mediated endocytosis (CME) in cells by an unknown mechanism. We examined whether its action and that of other APDs might be mediated by the GTPase activity of dynamin. Eight of eight phenothiazine-derived APDs inhibited dynamin I (dynI) in the 2-12µm range, the most potent being trifluoperazine (IC50 2.6±0.7µm). They also inhibited dynamin II (dynII) at similar concentrations. Typical and atypical APDs not based on the phenothiazine scaffold were 8- to 10-fold less potent (haloperidol and clozapine) or were inactive (droperidol, olanzapine and risperidone). Kinetic analysis showed that phenothiazine-derived APDs were lipid competitive, while haloperidol was uncompetitive with lipid. Accordingly, phenothiazine-derived APDs inhibited dynI GTPase activity stimulated by lipids but not by various SH3 domains. All dynamin-active APDs also inhibited transferrin (Tfn) CME in cells at related potencies. Structure-activity relationships (SAR) revealed dynamin inhibition to be conferred by a substituent group containing a terminal tertiary amino group at the N2 position. Chlorpromazine was previously proposed to target AP-2 recruitment in the formation of clathrin-coated vesicles (CCV). However, neither chlorpromazine nor thioridazine affected AP-2 interaction with amphiphysin or clathrin. Super-resolution microscopy revealed that chlorpromazine blocks neither clathrin recruitment by AP-2, nor AP-2 recruitment, showing that CME inhibition occurs downstream of CCV formation. Overall, potent dynamin inhibition is a shared characteristic of phenothiazine-derived APDs, but not other typical or atypical APDs, and the data indicate that dynamin is their likely in-cell target in endocytosis.

DOI10.1111/tra.12272
2015Cossar PJ, Hizartzidis L, Simone MI, McCluskey A, Gordon CP, 'The expanding utility of continuous flow hydrogenation.', Org Biomol Chem, 13 7119-7130 (2015)
DOI10.1039/c5ob01067eAuthor URL
Co-authorsMichela Simone
2015Rixson JE, Abraham JR, Egoshi Y, Skelton BW, Young K, Gilbert J, et al., 'The synthesis and biological activity of novel anthracenone-pyranones and anthracenone-furans', Bioorganic and Medicinal Chemistry, (2015)

An efficient and divergent methodology for the synthesis of new anthracenone-pyranones and anthracenone-furans is described. Key reactions discussed in these syntheses include an aldehyde promoted annulation with a ß-keto-sulfoxide, a domino alkyne insertion/carbonylation/Nu-acylation and a DMEDA promoted Castro-Stephens reaction. We also report the in vitro growth inhibition of these compounds in a range of human cancer cells. The natural product BE-26554A displayed good cell growth activity on BE2-C neuroblastoma and SMA glioblastoma cell lines at 0.17 and 0.16µM (GI50), respectively. Of note, were a CF3 functionalised anthracenone 4-pyranone (chromone) derivative 22, and an anthracenone-furan derivative 54 which displayed 0.20µM and 0.38µM growth inhibition, respectively, in the BE2-C neuroblastoma cell line.

DOI10.1016/j.bmc.2015.04.032
Co-authorsJennette Sakoff
2015Daniel JA, Chau N, Abdel-Hamid MK, Hu L, von Kleist L, Whiting A, et al., 'Phenothiazine-Derived Antipsychotic Drugs Inhibit Dynamin and Clathrin-Mediated Endocytosis', Traffic, 16 635-654 (2015)

Chlorpromazine is a phenothiazine-derived antipsychotic drug (APD) that inhibits clathrin-mediated endocytosis (CME) in cells by an unknown mechanism. We examined whether its action and that of other APDs might be mediated by the GTPase activity of dynamin. Eight of eight phenothiazine-derived APDs inhibited dynamin I (dynI) in the 2-12 µm range, the most potent being trifluoperazine (IC50 2.6 ± 0.7 µm). They also inhibited dynamin II (dynII) at similar concentrations. Typical and atypical APDs not based on the phenothiazine scaffold were 8- to 10-fold less potent (haloperidol and clozapine) or were inactive (droperidol, olanzapine and risperidone). Kinetic analysis showed that phenothiazine-derived APDs were lipid competitive, while haloperidol was uncompetitive with lipid. Accordingly, phenothiazine-derived APDs inhibited dynI GTPase activity stimulated by lipids but not by various SH3 domains. All dynamin-active APDs also inhibited transferrin (Tfn) CME in cells at related potencies. Structure-activity relationships (SAR) revealed dynamin inhibition to be conferred by a substituent group containing a terminal tertiary amino group at the N2 position. Chlorpromazine was previously proposed to target AP-2 recruitment in the formation of clathrin-coated vesicles (CCV). However, neither chlorpromazine nor thioridazine affected AP-2 interaction with amphiphysin or clathrin. Super-resolution microscopy revealed that chlorpromazine blocks neither clathrin recruitment by AP-2, nor AP-2 recruitment, showing that CME inhibition occurs downstream of CCV formation. Overall, potent dynamin inhibition is a shared characteristic of phenothiazine-derived APDs, but not other typical or atypical APDs, and the data indicate that dynamin is their likely in-cell target in endocytosis.

DOI10.1111/tra.12272
2015Reid AT, Anderson AL, Roman SD, McLaughlin EA, McCluskey A, Robinson PJ, et al., 'Glycogen synthase kinase 3 regulates acrosomal exocytosis in mouse spermatozoa via dynamin phosphorylation.', FASEB J, 29 2872-2882 (2015)
DOI10.1096/fj.14-265553Author URL
Co-authorsJohn Aitken, Shaun Roman, Brett Nixon, Eileen Mclaughlin
2014Abdel-Hamid MK, McCluskey A, 'In Silico docking, molecular dynamics and binding energy insights into the bolinaquinone-clathrin terminal domain binding site', Molecules, 19 6609-6622 (2014) [C1]

Clathrin-mediated endocytosis (CME) is a process that regulates selective internalization of important cellular cargo using clathrin-coated vesicles. Perturbation of this process has been linked to many diseases including cancer and neurodegenerative conditions. Chemical proteomics identified the marine metabolite, 2-hydroxy-5-methoxy-3-(((1S,4aS,8aS)-1,4a,5-Trimethyl-1,2,3,4,4a,7, 8,8a-octahydronaphthalen-2-yl)methyl)cyclohexa-2,5-diene-1,4-dione (bolinaquinone) as a clathrin inhibitor. While being an attractive medicinal chemistry target, the lack of data about bolinaquinone's mode of binding to the clathrin enzyme represents a major limitation for its structural optimization. We have used a molecular modeling approach to rationalize the observed activity of bolinaquinone and to predict its mode of binding with the clathrin terminal domain (CTD). The applied protocol started by global rigid-protein docking followed by flexible docking, molecular dynamics and linear interaction energy calculations. The results revealed the potential of bolinaquinone to interact with various pockets within the CTD, including the clathrin-box binding site. The results also highlight the importance of electrostatic contacts over van der Waals interactions for proper binding between bolinaquinone and its possible binding sites. This study provides a novel model that has the potential to allow rapid elaboration of bolinaquinone analogues as a new class of clathrin inhibitors. © 2014 by the authors.

DOI10.3390/molecules19056609
CitationsScopus - 1Web of Science - 1
2014Zayas H, Holdsworth CI, Bowyer MC, McCluskey A, 'Evaluation of 4-substituted styrenes as functional monomers for the synthesis of theophylline-specific molecularly imprinted polymers.', Org Biomol Chem, 12 6994-7003 (2014) [C1]
DOI10.1039/c4ob00517aAuthor URL
Co-authorsMichael Bowyer, Clovia Holdsworth
2014Hizartzidis L, Tarleton M, Gordon CP, McCluskey A, 'Chemoselective flow hydrogenation approaches to isoindole-7-carboxylic acids and 7-oxa-bicyclio[2.2.1]heptanes', RSC Advances, 4 9709-9722 (2014) [C1]

Two libraries of highly decorated norcantharidin analogues were accessed via a series of sequential chemoselective flow hydrogenations and solvent-free transformations. Utilising a 10% Pd/C catalyst, modifications to reaction parameters (H2 pressure, temperature and flow rate conditions) allowed facile access to effect selective direct reductive aminations and olefin reductions in the presence of furan, benzyl and nitrile moieties were established. The use of 20% Pd(OH)2/C; Pd tetrakis; 5% Pt/C (sulfided) gave mixtures of furan and olefin (both reduced) and olefin reduced products. RuO2; 0.5% Re/C and Re2O7 resulted in no reduction. Concurrent olefin and nitrile reduction was achieved in the presence of furan moieties by employing a RANEY® nickel catalyst. In total, 31 reaction conditions were examined using less than 200 mg of reagents allowing optimised conditions to be efficiently determined. These optimised hydrogenation conditions afforded desired analogues in near quantitative yields thus removing the requirements of reaction workup and chromatography. © 2014 The Royal Society of Chemistry.

DOI10.1039/c3ra47657j
CitationsScopus - 1Web of Science - 1
2014Al Otaibi A, Gordon CP, Gilbert J, Sakoff JA, McCluskey A, 'The influence of ionic liquids on the Knoevenagel condensation of 1H-pyrrole-2-carbaldehyde with phenyl acetonitriles-cytotoxic 3-substituted-(1H-pyrrol-2-yl)acrylonitriles', RSC Advances, 4 19806-19813 (2014) [C1]

The Knoevenagel condensation of a series of substituted phenyl acetonitriles with 1H-pyrrole-2-carbaldehyde was examined in seven 1-butyl-3-methylimidazolium based ionic liquids and three protic ionic liquids. Of these [BMIM][Br] and [BMIM][OH], with catalytic piperidine, proved most efficient affording 3-substituted-(1H-pyrrol-2-yl)acrylonitriles 3-17 in good to excellent yields (98%) whilst utilisation of the protic ionic liquid propyl ammonium nitrate resulted in reduced yields (0-66%). Screening of the 3-substituted-(1H-pyrrol-2-yl)acrylonitriles analogues 3-17 against a panel of 11 cancer cell lines and one normal cell line allowed the identification of a series of compounds with broad spectrum cytotoxicity, but more interestingly a significant degree of MCF-7 breast cancer cell line specificity was evident with 6 (7 to >25 fold) and 13 (5.7 to >80 fold). Other analogues show high level of efficacy against specific cell lines with 10 showing excellent activity against MCF-7 (GI50 = 1.7 µM) and A431 (GI50 = 2.8 µM) cell lines. The most promising of the compounds identified herein were the 4-CF3 substituted 10 and the 3,4-dichloro substituted 13 with excellent activities against MCF-7 and A431 cell lines. The 3,4-dichloro-13 was a 0.56 µM potent inhibitor of MCF-7 cell growth. © 2014 the Partner Organisations.

DOI10.1039/c3ra47418f
Co-authorsJennette Sakoff
2014Hizartzidis L, Cossar PJ, Robertson MJ, Simone MI, Young KA, McCluskey A, Gordon CP, 'Expanding the utility of flow hydrogenation - A robust protocol restricting hydrodehalogenation', RSC Advances, 4 56743-56748 (2014) [C1]

A commonly observed limitation of conducting hydrogenations under flow chemistry conditions is hydrodehalogenation. In a bid to circumvent this limitation a series of hydrogenation catalysts were screened, with 5% Pt/C (sulfided) catalyst identified as an effective catalyst to selectively effect reductive aminations, nitro reduction, and alkene reductions in the presence of halogen atoms. Additionally the optimised protocol cleanly reduced imines in the presence of a furan moiety indicating potential amenability to other labile functionalities.

DOI10.1039/c4ra09605c
CitationsScopus - 1Web of Science - 1
Co-authorsMichela Simone
2014Stahlschmidt W, Robertson MJ, Robinson PJ, McCluskey A, Haucke V, 'Clathrin terminal domain-ligand interactions regulate sorting of mannose 6-phosphate receptors mediated by AP-1 and GGA adaptors', Journal of Biological Chemistry, 289 4906-4918 (2014) [C1]

Background: Clathrin is a coat protein involved in intracellular membrane traffic. Results: Acute inhibition of clathrin-ligand association by Pitstop® compounds perturbs intracellular receptor sorting mediated by AP-1 and GGA adaptors. Conclusion: Clathrin is required for intracellular receptor sorting by AP-1 and GGA adaptor proteins. Significance: Pitstop® compounds are tools for the functional dissection of intracellular trafficking pathways. © 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

DOI10.1074/jbc.M113.535211
CitationsScopus - 2Web of Science - 3
2014Stahlschmidt W, Robertson MJ, Robinson PJ, McCluskey A, Haucke V, 'Clathrin Terminal Domain- Ligand Interactions Regulate Sorting of Mannose 6-Phosphate Receptors Mediated by AP-1 and GGA Adaptors*', JOURNAL OF BIOLOGICAL CHEMISTRY, 289 4906-4918 (2014) [C1]
DOI10.1074/jbc.M113.535211Author URL
CitationsScopus - 2Web of Science - 3
2014Stahlschmidt W, Robertson MJ, Robinson PJ, McCluskey A, Haucke V, 'Clathrin terminal domain-ligand interactions regulate sorting of mannose 6-phosphate receptors mediated by AP-1 and GGA adaptors', Journal of Biological Chemistry, 289 4906-4918 (2014) [C1]

Background: Clathrin is a coat protein involved in intracellular membrane traffic. Results: Acute inhibition of clathrin-ligand association by Pitstop® compounds perturbs intracellular receptor sorting mediated by AP-1 and GGA adaptors. Conclusion: Clathrin is required for intracellular receptor sorting by AP-1 and GGA adaptor proteins. Significance: Pitstop® compounds are tools for the functional dissection of intracellular trafficking pathways. © 2014 by The American Society for Biochemistry and Molecular Biology, Inc.

DOI10.1074/jbc.M113.535211
CitationsScopus - 2
2014MacGregor KA, Robertson MJ, Young KA, von Kleist L, Stahlschmidt W, Whiting A, et al., 'Development of 1,8-Naphthalimides as Clathrin Inhibitors', JOURNAL OF MEDICINAL CHEMISTRY, 57 131-143 (2014) [C1]
DOI10.1021/jm4015263Author URL
CitationsScopus - 3Web of Science - 2
2014Macgregor KA, Abdel-Hamid MK, Odell LR, Chau N, Whiting A, Robinson PJ, McCluskey A, 'Development of quinone analogues as dynamin GTPase inhibitors', European Journal of Medicinal Chemistry, 85 191-206 (2014) [C1]

Virtual screening of the ChemDiversity and ChemBridge compound databases against dynamin I (dynI) GTPase activity identified 2,5-bis-(benzylamino)-1,4- benzoquinone 1 as a 273 ± 106 µM inhibitor. In silico lead optimization and focused library-led synthesis resulted in the development of four discrete benzoquinone/naphthoquinone based compound libraries comprising 54 compounds in total. Sixteen analogues were more potent than lead 1, with 2,5-bis-(4-hydroxyanilino)-1,4-benzoquinone (45) and 2,5-bis(4-carboxyanilino)- 1,4-benzoquinone (49) the most active with IC50 values of 11.1 ± 3.6 and 10.6 ± 1.6 µM respectively. Molecular modelling suggested a number of hydrogen bonding and hydrophobic interactions were involved in stabilization of 49 within the dynI GTP binding site. Six of the most active inhibitors were evaluated for potential inhibition of clathrin-mediated endocytosis (CME). Quinone 45 was the most effective CME inhibitor with an IC50(CME) of 36 ± 16 µM. © 2014 Published by Elsevier Masson SAS. All rights reserved.

DOI10.1016/j.ejmech.2014.06.070
2014Dyson L, Young KA, McCluskey A, Wright AD, Sakoff JA, 'Synthesis and anticancer activity of focused compound libraries from the natural product lead, oroidin', Bioorganic and Medicinal Chemistry, 22 1690-1699 (2014) [C1]

Oroidin (1), (E)-N-(3-(2-amino-1H-imidazol-4-yl)allyl)-4,5-dibromo-1H- pyrrole-2-carboxamide, is a pyrrole alkaloid isolated from the marine sponge Agelas oroides. Routine screening in a panel of twelve cancer cell lines revealed 1 to be poorly cytotoxic with the 50% growth inhibition concentration (GI) of 42 µM in MCF-7 (breast) cells and 24 µM in A2780 (ovarian) cells and >50 µM in all other cell lines tested. The development of eight focused libraries comprising thirty compounds total identified N-(biphenyl-4-ylmethyl)-1H-pyrrole-2-carboxamide (4l), N-benzyl-4,5-dibromo-1H- pyrrole-2-carboxamide (5a) and N-(biphenyl-4-ylmethyl)-4,5-dibromo-1H-pyrrole-2- carboxamide (5l) as potent inhibitors of cell growth in our panel of cell lines. Of these compounds GI values of <5 µM were observed with 4l against HT29 (colon) and SW480 (colon); 5a against HT29; and 5l against HT29, SW480, MCF-7, A431 (skin), Du145 (prostate), BE2-C (neuroblastoma) and MIA (pancreas) cell lines. As a cancer class, colon cancer appears to be more sensitive to the oroidin series of compounds, with analogue 5l being the most active. © 2014 Elsevier Ltd. All rights reserved.

DOI10.1016/j.bmc.2014.01.021
CitationsScopus - 2Web of Science - 3
Co-authorsJennette Sakoff
2014Cleland D, Olsson GD, Karlsson BCG, Nicholls IA, McCluskey A, 'Molecular dynamics approaches to the design and synthesis of PCB targeting molecularly imprinted polymers: interference to monomer-template interactions in imprinting of 1,2,3-trichlorobenzene', ORGANIC & BIOMOLECULAR CHEMISTRY, 12 844-853 (2014) [C1]
DOI10.1039/c3ob42399aAuthor URL
CitationsScopus - 4Web of Science - 4
2014Trinh TN, Hizartzidis L, Lin AJ, Harman DG, McCluskey A, Gordon CP, 'An efficient continuous flow approach to furnish furan-based biaryls', Organic & Biomolecular Chemistry, 12 9562-9571 (2014) [C1]
DOI10.1039/c4ob01641f
CitationsScopus - 1Web of Science - 1
2014Booker K, Holdsworth CI, Doherty CM, Hill AJ, Bowyer MC, McCluskey A, 'Ionic liquids as porogens for molecularly imprinted polymers: Propranolol, a model study', Organic and Biomolecular Chemistry, 12 7201-7210 (2014) [C1]

The selectivity and rebinding capacity of molecularly imprinted polymers selective for propranolol (1) using the room temperature ionic liquids [BMIM][BF4], [BMIM][PF6], [HMIM][PF6] and [OMIM][PF6] and CHCl3 were examined. The observed IF (imprinting factor) values for MIPBF4, MIPPF6 and MIP CHCl3 were 1.0, 1.98 and 4.64, respectively. The longer chain HMIM and OMIM systems returned lower IF values of 1.1 and 2.3, respectively. MIP PF6 also showed a ~25% binding capacity reduction vs. MIP CHCl3 (5 µmol g-1vs. 7 µmol g-1 respectively). MIPCHCl3 and MIPPF6 differed in terms of BET surface area (306 m2 g-1vs. 185 m2 g -1), pore size (1.10 and 2.19 nm vs. 0.97 and 7.06 nm), the relative number of pores (Type A: 10.4 vs. 7.5%; Type B: 8.5 vs. 3.0%), and surface zeta potential (-37.9 mV vs. -20.3 mV). The MIP specificity for 1 was examined by selective rebinding studies with caffeine (2) and ephedrine (3). MIP PF6 rebound higher quantities of 2 than MIPCHCl3, but this was largely due to non-specific binding. Both MIPCHCl3 and MIP PF6 showed a higher affinity for 3 than for 2. Reduction in the Room Temperature Ionic Liquid (RTIL) porogen volume had little impact on the polymer morphology, but did result in a modest decrease in IF from 2.6 to 2.3 and in the binding capacity (30% to 19%). MIPCHCl3 retained the highest template specificity on rebinding from CHCl3 (IF = 4.6) dropping to IF = 0.6 in MeOH/[BMIM][PF6]. The MIPCHCl3 binding capacity remained constant using CHCl3, CH2Cl2 and MeOH (46-52%), dropped to 6% on addition of [BMIM][PF6] and increased to 83% in H2O (but at the expense of specificity with IFH2O = 1.4). MIPPF6 rebinding from MeOH saw an increase in specific rebinding to IF = 4.9 and also an increase in binding capacity to 48% when rebinding 1 from MeOH and to 42% and 45% with H2O and CH2Cl2, respectively, although in the latter case the increased capacity was at the cost of specificity with IFCH2Cl2 = 1.2. Overall the MIPPF6 capacity and specificity were enhanced on addition of MeOH. This journal is © the Partner Organisations 2014.

DOI10.1039/c4ob00547c
CitationsScopus - 1Web of Science - 1
Co-authorsMichael Bowyer, Clovia Holdsworth
2014Gordon CP, Hizartzidis L, Tarleton M, Sakoff JA, Gilbert J, Campbell BE, et al., 'Discovery of acrylonitrile-based small molecules active against Haemonchus contortus', MEDCHEMCOMM, 5 159-164 (2014) [C1]
DOI10.1039/c3md00255aAuthor URL
CitationsScopus - 2Web of Science - 3
Co-authorsJennette Sakoff
2014Trinh TN, McLaughlin EA, Gordon CP, McCluskey A, 'Hedgehog signalling pathway inhibitors as cancer suppressing agents', MedChemComm, 5 117-133 (2014) [C1]

The Hedgehog (Hh) signalling pathway plays a pivotal role in the spatial and temporal regulation of cell proliferation and differentiation. By controlling the correct maturation of developing tissues and ensuring attainment of the correct size, position and the presence of fully functioning cellular structures, the Hh plays a pivotal role in development. Conversely aberrant Hh signalling is involved in Gorlin syndrome, basal cell carcinoma (the most common cancer in the world), and more than one third of all human medulloblastoma cases. In all of these cases, it is believed that deregulated Hh signalling leads to increased cell proliferation and tumour formation. Inhibition of the Hedgehog signalling pathway, is a recently validated anti-cancer drug target, with vismodegib (Erivedge¿), approved by the U.S. Food and Drug Administration for the treatment of adult basal cell carcinoma. In this perspective we outline the current state of Hh pathway inhibitors with a particular focus on potential limitations of upstream Hh pathway inhibition in relation to resistance mutations and crosstalk pathways. Together, these limitations indicate that inhibition of downstream components, specifically the Gli family of transcription factors, may represent a next generation approach to suppress tumours associated with aberrant Hh pathway signalling. © 2014 The Royal Society of Chemistry.

DOI10.1039/c3md00334e
CitationsScopus - 5Web of Science - 4
Co-authorsEileen Mclaughlin
2014Robertson MJ, Deane FM, Robinson PJ, McCluskey A, 'Synthesis of Dynole 34-2, Dynole 2-24 and Dyngo 4a for investigating dynamin GTPase', Nature Protocols, 9 851-870 (2014) [C1]

Dynamin is a large GTPase with roles in membrane fission during clathrin-mediated endocytosis, in actin dynamics and in cytokinesis. Defects in dynamin have been linked to human diseases. The synthesis of a dynamin modulator toolkit comprising two different inhibitor classes is described. The first series comprises Dynole 34-2, Dynole 2-24 and the inactive control Dynole 31-2. The Dynole compounds act on the dynamin G domain, are not GTP competitive and can be synthesized in 2-3 d. Knoevenagel condensation of 1-(3-(dimethylamino) propyl)-1H-indole-3-carbaldehyde (1) with cyanoamides (2 and 3) affords Dynole 31-2 and Dynole 34-2, respectively. Reductive amination of 1 with decylamine gives Dynole 2-24. The second series acts at an allosteric site in the G domain of dynamin and comprises Dyngo 4a and Dyngo Ø (inactive control). Both are synthesized in an overnight reaction via condensation of 3-hydroxy-2-naphthoic hydrazide with 2,4,5-trihydroxybenzaldehyde to afford Dyngo 4a, or with benzaldehyde to afford Dyngo Ø. © 2014 Nature America, Inc. All rights reserved.

DOI10.1038/nprot.2014.046
CitationsScopus - 3Web of Science - 3
2014Robertson MJ, Deane FM, Stahlschmidt W, Von Kleist L, Haucke V, Robinson PJ, McCluskey A, 'Synthesis of the Pitstop family of clathrin inhibitors', Nature Protocols, 9 1592-1606 (2014) [C1]

This protocol describes the synthesis of two classes of clathrin inhibitors, Pitstop 1 and Pitstop 2, along with two inactive analogs that can be used as negative controls (Pitstop inactive controls, Pitnot-2 and Pitnot-2-100). Pitstop-induced inhibition of clathrin TD function acutely interferes with clathrin-mediated endocytosis (CME), synaptic vesicle recycling and cellular entry of HIV, whereas clathrin-independent internalization pathways and secretory traffic proceed unperturbed; these reagents can, therefore, be used to investigate clathrin function, and they have potential pharmacological applications. Pitstop 1 is synthesized in two steps: sulfonation of 1,8-naphthalic anhydride and subsequent reaction with 4-amino(methyl)aniline. Pitnot-1 results from the reaction of 4-amino(methyl)aniline with commercially available 4-sulfo-1,8-naphthalic anhydride potassium salt. Reaction of 1-naphthalene sulfonyl chloride with pseudothiohydantoin followed by condensation with 4-bromobenzaldehyde yields Pitstop 2. The synthesis of the inactive control commences with the condensation of 4-bromobenzaldehyde with the rhodanine core. Thioketone methylation and displacement with 1-napthylamine affords the target compound. Although Pitstop 1-series compounds are not cell permeable, they can be used in biochemical assays or be introduced into cells via microinjection. The Pitstop 2-series compounds are cell permeable. The synthesis of these compounds does not require specialist equipment and can be completed in 3-4 d. Microwave irradiation can be used to reduce the synthesis time. The synthesis of the Pitstop 2 family is easily adaptable to enable the synthesis of related compounds such as Pitstop 2-100 and Pitnot-2-100. The procedures are also simple, efficient and amenable to scale-up, enabling cost-effective in-house synthesis for users of these inhibitor classes.

DOI10.1038/nprot.2014.106
2014Sobinoff AP, Sutherland JM, Beckett EL, Stanger SJ, Johnson R, Jarnicki AG, et al., 'Damaging legacy: maternal cigarette smoking has long-term consequences for male offspring fertility.', Hum Reprod, 29 2719-2735 (2014) [C1]
DOI10.1093/humrep/deu235Author URL
CitationsScopus - 2Web of Science - 2
Co-authorsPhilip Hansbro, Eileen Mclaughlin
2013Stehn JR, Haass NK, Bonello T, Desouza M, Kottyan G, Treutlein H, et al., 'A Novel Class of Anticancer Compounds Targets the Actin Cytoskeleton in Tumor Cells', CANCER RESEARCH, 73 5169-5182 (2013) [C1]
DOI10.1158/0008-5472.CAN-12-4501Author URL
CitationsScopus - 17Web of Science - 14
2013Gordon CP, Venn-Brown B, Robertson MJ, Young KA, Chau N, Mariana A, et al., 'Development of Second-Generation Indole-Based Dynamin GTPase Inhibitors', Journal of Medicinal Chemistry, 56 46-59 (2013) [C1]
DOI10.1021/jm300844mAuthor URL
CitationsScopus - 11Web of Science - 10
2013Sobinoff AP, Beckett EL, Jarnicki AG, Sutherland JM, McCluskey A, Hansbro PM, McLaughlin EA, 'Scrambled and fried: Cigarette smoke exposure causes antral follicle destruction and oocyte dysfunction through oxidative stress', TOXICOLOGY AND APPLIED PHARMACOLOGY, 271 156-167 (2013) [C1]
DOI10.1016/j.taap.2013.05.009Author URL
CitationsScopus - 8Web of Science - 7
Co-authorsEileen Mclaughlin, Philip Hansbro
2013Harper CB, Popoff MR, McCluskey A, Robinson PJ, Meunier FA, 'Targeting membrane trafficking in infection prophylaxis: Dynamin inhibitors', Trends in Cell Biology, 23 90-101 (2013) [C1]
DOI10.1016/j.tcb.2012.10.007Author URL
CitationsScopus - 19Web of Science - 16
2013Tarleton M, Dyson L, Gilbert J, Sakoff JA, McCluskey A, 'Focused library development of 2-phenylacrylamides as broad spectrum cytotoxic agents', BIOORGANIC & MEDICINAL CHEMISTRY, 21 333-347 (2013) [C1]
DOI10.1016/j.bmc.2012.10.003Author URL
CitationsScopus - 5Web of Science - 4
Co-authorsJennette Sakoff
2013McCluskey A, Daniel JA, Hadzic G, Ngoc C, Clayton EL, Mariana A, et al., 'Building a Better Dynasore: The Dyngo Compounds Potently Inhibit Dynamin and Endocytosis', TRAFFIC, 14 1272-1289 (2013)
DOI10.1111/tra.12119Author URL
CitationsWeb of Science - 18
Co-authorsJennette Sakoff
2013McCluskey A, Daniel JA, Hadzic G, Chau N, Clayton EL, Mariana A, et al., 'Building a Better Dynasore: The Dyngo Compounds Potently Inhibit Dynamin and Endocytosis', Traffic, 14 1272-1289 (2013) [C1]
DOI10.1111/tra.12119
CitationsScopus - 20
Co-authorsJennette Sakoff
2013Smith CM, Haucke V, McCluskey A, Robinson PJ, Chircop M, 'Inhibition of clathrin by pitstop 2 activates the spindle assembly checkpoint and induces cell death in dividing HeLa cancer cells', MOLECULAR CANCER, 12 (2013) [C1]
DOI10.1186/1476-4598-12-4Author URL
CitationsScopus - 4Web of Science - 5
2013Cleland D, McCluskey A, 'An extreme vertices mixture design approach to the optimisation of 1,2,3-trichlorobenzene specific molecularly imprinted polymers', ORGANIC & BIOMOLECULAR CHEMISTRY, 11 4672-4679 (2013) [C1]
DOI10.1039/c3ob27375jAuthor URL
CitationsScopus - 3Web of Science - 3
2013Deane FM, O'Sullivan EC, Maguire AR, Gilbert J, Sakoff JA, McCluskey A, McCarthy FO, 'Synthesis and evaluation of novel ellipticines as potential anti-cancer agents', Organic & Biomolecular Chemistry, 11 1334-1344 (2013) [C1]
DOI10.1039/c2ob27186aAuthor URL
CitationsScopus - 7Web of Science - 9
Co-authorsJennette Sakoff
2013Brisbane C, McCluskey A, Bowyer M, Holdsworth CI, 'Molecularly imprinted films of acrylonitrile/methyl methacrylate/acrylic acid terpolymers: influence of methyl methacrylate in the binding performance of L-ephedrine imprinted films', Organic & Biomolecular Chemistry, 11 2872-2884 (2013) [C1]
DOI10.1039/c3ob40332gAuthor URL
CitationsScopus - 1Web of Science - 1
Co-authorsClovia Holdsworth, Michael Bowyer
2013Cleland D, McCluskey A, 'The use of effective fragment potentials in the design and synthesis of molecularly imprinted polymers for the group recognition of PCBs', Organic and Biomolecular Chemistry, 11 4646-4656 (2013) [C1]
DOI10.1039/c3ob27168dAuthor URL
CitationsScopus - 4Web of Science - 3
2013Zhang J, Luo S-X, McCluskey A, Lawrance GA, 'Metal-Templated Macrocycle Synthesis in an Ionic Liquid: A Comparison With Reaction in Protic Solvents', Synthesis and Reactivity in Inorganic, Metal Organic, and Nano Metal Chemistry, 43 1-5 (2013) [C1]
DOI10.1080/15533174.2011.652275Author URL
CitationsScopus - 1Web of Science - 1
Co-authorsGeoffrey Lawrance
2013McGeachie AB, Odell LR, Quan A, Daniel JA, Chau N, Hill TA, et al., 'Pyrimidyn compounds: Dual-action small molecule pyrimidine-based dynamin inhibitors', ACS Chemical Biology, 8 1507-1518 (2013) [C1]
DOI10.1021/cb400137p
CitationsScopus - 6Web of Science - 6
Co-authorsJennette Sakoff
2012Turner NW, Holdsworth CI, McCluskey A, Bowyer MC, 'N-2-propenyl-(5-dimethylamino)-1-naphthalene sulfonamide, a novel fluorescent monomer for the molecularly imprinted polymer-based detection of 2,4-dinitrotoluene in the gas phase', Australian Journal of Chemistry, 65 1405-1412 (2012) [C1]
CitationsScopus - 3Web of Science - 3
Co-authorsMichael Bowyer, Clovia Holdsworth
2012Reid AT, Lord T, Stanger SJ, Roman SD, McCluskey A, Robinson PJ, et al., 'Dynamin regulates specific membrane fusion events necessary for acrosomal exocytosis in mouse spermatozoa', Journal of Biological Chemistry, 287 37659-37672 (2012) [C1]
CitationsScopus - 10Web of Science - 9
Co-authorsBrett Nixon, John Aitken, Shaun Roman
2012Robinson K, McCluskey A, Attalla MI, 'The effect molecular structural variations has on the CO2 absorption characteristics of heterocyclic amines', ACS Symposium Series, 1097 1-27 (2012)

This chapter details the novel application of in-situ Attenuated Reflectance Fourier Transform Infrared (ATR FT-IR) spectroscopy to investigate the effect molecular structural variation has on the CO2 absorption characteristics of heterocyclic amines. The reaction between CO2 and a subset of structurally variant amines were analyzed including piperidine, as well as commercially available functionalized piperidine derivatives, for example, those with methyl-, hydroxyl- and hydroxyalkyl- substituents. This new technique uses an ATR probe optically coupled to an FT-IR spectrometer to monitor the reaction species evolving in solution as CO2 is being absorbed into solution. The effect of molecular structural variations on CO 2 absorption was then assessed in relation to the IR identifiable ionic reaction products, CO2 absorption capacity and the mass-transfer coefficient at zero loading. © 2012 American Chemical Society.

DOI10.1021/bk-2012-1097.ch001
CitationsScopus - 1
2012Tarleton MJ, Gilbert J, Sakoff JA, McCluskey A, 'Synthesis and anticancer activity of a series of norcantharidin analogues', European Journal of Medicinal Chemistry, 54 573-581 (2012) [C1]
CitationsScopus - 7Web of Science - 7
Co-authorsJennette Sakoff
2012Tarleton MJ, Gilbert J, Sakoff JA, McCluskey A, 'Cytotoxic 2-phenyacrylnitriles, the importance of the cyanide moiety and discovery of potent broad spectrum cytotoxic agents', European Journal of Medicinal Chemistry, 57 65-73 (2012) [C1]
DOI10.1016/j.ejmech.2012.09.019
CitationsScopus - 8Web of Science - 8
Co-authorsJennette Sakoff
2012Tarleton MJ, Bernhardt PV, McCluskey A, 'Crystal structures of (3R,3aR,4S,7R,7aS)-3-(Allyloxy)hexahydro-4,7-epoxyisobenzofuran-1(3H)-on e and (3S,3aR,4S,7R,7aS)-3-((E)-But-2-en-1-yloxy)hexahydro-4,7-epoxyisobenzofu ran-1(3H)-one: Confirmation of NMR predicted stereocentre geometry', Journal of Chemical Crystallography, 42 639-644 (2012) [C1]
2012Robinson KM, McCluskey A, Attalla MI, 'An ATR-FTIR study on the effect of molecular structural variations on the CO2 absorption characteristics of Heterocyclic Amines, Part II', Chemphyschem, 13 2331-2341 (2012) [C1]
CitationsScopus - 5Web of Science - 5
2012Daniel JA, Malladi CS, Kettle E, McCluskey A, Robinson PJ, 'Analysis of synaptic vesicle endocytosis in synaptosomes by high-content screening', Nature Protocols, 7 1439-1455 (2012) [C1]
CitationsScopus - 8Web of Science - 7
2012Nguyen TH, Maucort G, Sullivan RKP, Schenning M, Lavidis NA, McCluskey A, et al., 'Actin- and dynamin-dependent maturation of bulk endocytosis restores neurotransmission following synaptic depletion', PLoS One, 7 e36913 (2012) [C1]
CitationsScopus - 8Web of Science - 7
2012Robertson MJ, Hadzic G, Ambrus JI, Pome DY, Hyde EDE, Whiting A, et al., 'The Rhodadyns, a new class of small molecule inhibitors of Dynamin GTPase Activity', ACS Medicinal Chemistry Letters, 3 352-356 (2012) [C1]
CitationsScopus - 10Web of Science - 10
2011Wright AD, McCluskey A, Robertson MJ, Macgregor KA, Gordon CP, Guenther J, 'Anti-malarial, anti-algal, anti-tubercular, anti-bacterial, anti-photosynthetic, and anti-fouling activity of diterpene and diterpene isonitriles from the tropical marine sponge Cymbastela hooperi', Organic and Biomolecular Chemistry, 9 400-407 (2011) [C1]
DOI10.1039/c0ob00326c
CitationsScopus - 18Web of Science - 16
2011Gordon CP, Young KA, Hizartzidis L, Deane FM, McCluskey A, 'Investigation of the one-pot synthesis of quinolin-2-(1H)-ones and the discovery of a variation of the three-component Ugi reaction', Organic and Biomolecular Chemistry, 9 1419-1428 (2011) [C1]
DOI10.1039/c0ob00029a
CitationsScopus - 3Web of Science - 3
2011Chircop M, Perera S, Mariana A, Lau H, Ma MPC, Gilbert J, et al., 'Inhibition of dynamin by dynole 34-2 induces cell death following cytokinesis failure in cancer cells', Molecular Cancer Therapeutics, 10 1553-1562 (2011) [C1]
DOI10.1158/1535-7163.mct-11-0067
CitationsScopus - 17Web of Science - 17
2011Tarleton MJ, Young KA, Unicomb E, McCluskey SN, Robertson MJ, Gordon CP, McCluskey A, 'A flow chemistry approach to norcantharidin analogues', Letters in Drug Design and Discovery, 8 568-574 (2011) [C1]
DOI10.2174/157018011795906730
CitationsScopus - 2Web of Science - 1
2011Robinson KM, McCluskey A, Attalla M, 'The effect molecular structural variations has on the CO2 absorption characteristics of heterocyclic amines', Energy Procedia, 4 224-231 (2011) [C1]
DOI10.1016/j.egypro.2011.01.045
CitationsScopus - 3Web of Science - 3
2011Tarleton MJ, Gilbert J, Robertson MJ, McCluskey A, Sakoff JA, 'Library synthesis and cytotoxicity of a family of 2-phenylacrylonitriles and discovery of an estrogen dependent breast cancer lead compound', MedChemComm, 2 31-37 (2011) [C1]
DOI10.1039/c0md00147c
CitationsScopus - 11Web of Science - 11
Co-authorsJennette Sakoff
2011Harper CB, Martin S, Nguyen TH, Daniels SJ, Lavidis NA, Popoff MR, et al., 'Dynamin inhibition blocks botulinum neurotoxin type A endocytosis in neurons and delays botulism', Journal of Biological Chemistry, 286 35966-35976 (2011) [C1]
DOI10.1074/jbc.m111.283879
CitationsScopus - 44Web of Science - 42
2011Gordon CP, Young KA, Robertson MJ, Hill TA, McCluskey A, 'An Ugi-intramolecular Diels-Alder route to highly substituted tetrahydroepoxyisoindole carboxamides', Tetrahedron, 67 554-561 (2011) [C1]
DOI10.1016/j.tet.2010.10.042
CitationsScopus - 4Web of Science - 5
2011Macgregor KA, McCluskey A, 'Ionic liquids accelerate access to N-substituted-1,8-naphthalimides', Tetrahedron Letters, 52 767-769 (2011) [C1]
DOI10.1016/j.tetlet.2010.12.015
CitationsScopus - 6Web of Science - 5
2011Tarleton MJ, McCluskey A, 'A flow chemistry route to 2-phenyl-3-(1H-pyrrol-2-yl)propan-1-amines', Tetrahedron Letters, 52 1583-1586 (2011) [C1]
DOI10.1016/j.tetlet.2011.01.096
CitationsScopus - 13Web of Science - 12
2011Von Kleist L, Stahlschmidt W, Bulut H, Gromova K, Puchkov D, Robertson MJ, et al., 'Role of the clathrin terminal domain in regulating coated pit dynamics revealed by small molecule inhibition', Cell, 146 471-484 (2011) [C1]
DOI10.1016/j.cell.2011.06.025
CitationsScopus - 124Web of Science - 117
2011Campbell BE, Hofmann A, McCluskey A, Gasser RB, 'Serine/threonine phosphatases in socioeconomically important parasitic nematodes - Prospects as novel drug targets?', Biotechnology Advances, 29 28-39 (2011) [C1]
DOI10.1016/j.biotechadv.2010.08.008
CitationsScopus - 20Web of Science - 17
2011Campbell BE, Tarleton MJ, Gordon CP, Sakoff JA, Gilbert J, McCluskey A, Gasser RB, 'Norcantharidin analogues with nematocidal activity in Haemonchus contortus', Bioorganic and Medicinal Chemistry Letters, 21 3277-3281 (2011) [C1]
DOI10.1016/j.bmcl.2011.04.031
CitationsScopus - 17Web of Science - 19
Co-authorsJennette Sakoff
2011Robertson MJ, Gordon CP, Gilbert J, McCluskey A, Sakoff JA, 'Norcantharimide analogues possessing terminal phosphate esters and their anti-cancer activity', Bioorganic & Medicinal Chemistry, 19 5734-5741 (2011) [C1]
DOI10.1016/j.bmc.2011.01.031
CitationsScopus - 9Web of Science - 10
Co-authorsJennette Sakoff
2011Robinson KM, McCluskey A, Attalla MI, 'An FTIR spectroscopic study on the effect of molecular structural variations on the CO2 absorption characteristics of heterocyclic amines', ChemPhysChem, 12 1088-1099 (2011) [C1]
DOI10.1002/cphc.201001056
CitationsScopus - 15Web of Science - 11
2010Joshi S, Perera S, Gilbert J, Smith CM, Mariana A, Gordon CP, et al., 'The Dynamin inhibitors MiTMAB and OcTMAB induce Cytokinesis failure and inhibit cell proliferation in human cancer cells', Molecular Cancer Therapeutics, 9 1995-2006 (2010) [C1]
DOI10.1158/1535-7163.mct-10-0161
CitationsScopus - 25Web of Science - 27
Co-authorsJennette Sakoff
2010Howes MT, Kirkham M, Riches J, Cortese K, Walser PJ, Simpson F, et al., 'Clathrin-independent carriers form a high capacity endocytic sorting system at the leading edge of migrating cells', Journal of Cell Biology, 190 675-691 (2010) [C1]
CitationsScopus - 94Web of Science - 91
2010Hill TA, Mariana A, Gordon CP, Odell L, Robertson MJ, McGeachie AB, et al., 'Iminochromene inhibitors of Dynamins I and II GTPase activity and Endocytosis', Journal of Medicinal Chemistry, 53 4094-4102 (2010) [C1]
DOI10.1021/jm100119c
CitationsScopus - 25Web of Science - 23
2010Odell L, Howan D, Gordon CP, Robertson MJ, Chau N, Mariana A, et al., 'The Pthaladyns: GTP competitive inhibitors of Dynamin I and II GTPase derived from virtual screening', Journal of Medicinal Chemistry, 53 5267-5280 (2010) [C1]
DOI10.1021/jm100442u
CitationsScopus - 28Web of Science - 24
2010Thaqi A, Scott JL, Gilbert J, Sakoff JA, McCluskey A, 'Synthesis and biological activity of Delta-5,6-norcantharimides: Importance of the 5,6-bridge', European Journal of Medicinal Chemistry, 45 1717-1723 (2010) [C1]
DOI10.1016/j.ejmech.2010.01.004
CitationsScopus - 20Web of Science - 18
Co-authorsJennette Sakoff
2010Bajsa J, McCluskey A, Gordon CP, Stewart SG, Hill TA, Sahu R, et al., 'The antiplasmodial activity of norcantharidin analogs', Bioorganic & Medicinal Chemistry Letters, 20 6688-6695 (2010) [C1]
DOI10.1016/j.bmcl.2010.09.004
CitationsScopus - 12Web of Science - 14
2010Turner NW, Holdsworth CI, Donne SW, McCluskey A, Bowyer MC, 'Microwave induced MIP synthesis: comparative analysis of thermal and microwave induced polymerisation of caffeine imprinted polymers', New Journal of Chemistry, 34 686-692 (2010) [C1]
DOI10.1039/b9nj00538b
CitationsScopus - 21Web of Science - 18
Co-authorsScott Donne, Michael Bowyer, Clovia Holdsworth
2010Chircop M, Malladi CS, Lian AT, Page SL, Zavortink M, Gordon CP, et al., 'Calcineurin activity is required for the completion of cytokinesis', Cellular and Molecular Life Sciences, 67 3725-3737 (2010) [C1]
DOI10.1007/s00018-010-0401-z
CitationsScopus - 15Web of Science - 14
2010Gordon CP, Byrne N, McCluskey A, 'A facile, protic ionic liquid route to N-substituted 5-hydroxy-4-methyl-3-oxoisoindoline-1-carboxamides and N-substituted 3-oxoisoindoline-4-carboxylic acids', Green Chemistry, 12 1000-1006 (2010) [C1]
DOI10.1039/b924835h
CitationsScopus - 19Web of Science - 20
2009Sauer B, Gilbert J, Sakoff JA, McCluskey A, 'Synthesis of 4-substituted-3-hydroxy-5-oxo-10-oxa-4-azatricyclo[5.2.1]dec-3-yl Acetic Acid Ethyl Esters as Norcantharidin Analogues', Letters in Drug Design & Discovery, 6 1-7 (2009) [C1]
DOI10.2174/157018009787158535
CitationsScopus - 7Web of Science - 7
Co-authorsJennette Sakoff
2009Turner NW, Holmes NP, Brisbane CE, McGeachie AB, Bowyer MC, McCluskey A, Holdsworth CI, 'Effect of template on the formation of phase-inversed molecularly imprinted polymer thin films: An assessment', Soft Matter, 5 3663-3671 (2009) [C1]
DOI10.1039/b902468a
CitationsScopus - 6Web of Science - 5
Co-authorsClovia Holdsworth, Michael Bowyer
2009Odell L, Chau N, Mariana A, Graham ME, Robinson PJ, McCluskey A, 'Azido and diazarinyl analogues of bis-tyrphostin as asymmetrical inhibitors of dynamin GTPase', Chemmedchem, 4 1182-1188 (2009) [C1]
DOI10.1002/cmdc.200900054
CitationsScopus - 19Web of Science - 19
2009Hill TA, Gordon CP, McGeachie AB, Venn-Brown B, Odell L, Chau N, et al., 'Inhibition of dynamin mediated endocytosis by the dynoles-synthesis and functional activity of a family of indoles', Journal of Medicinal Chemistry, 52 3762-3773 (2009) [C1]
DOI10.1021/jm900036m
CitationsScopus - 62Web of Science - 61
Co-authorsJennette Sakoff
2009Zayas HA, Bowyer MC, Gordon CP, Holdsworth CI, McCluskey A, 'Synthesis of biaryl-styrene monomers by microwave-assisted Suzuki coupling', Tetrahedron Letters, 50 5894-5895 (2009) [C1]
DOI10.1016/j.tetlet.2009.07.117
CitationsScopus - 9Web of Science - 8
Co-authorsMichael Bowyer, Clovia Holdsworth
2009Holland IP, McCluskey A, Sakoff JA, Gilbert J, Chau N, Robinson PJ, et al., 'Steroids from an Australian Sponge Psammoclema sp', Journal of Natural Products, 72 102-106 (2009) [C1]
DOI10.1021/np800688f
CitationsScopus - 4Web of Science - 3
Co-authorsJennette Sakoff
2009Whitehead JA, Zhang J, McCluskey A, Lawrance GA, 'Comparative leaching of a sulfidic gold ore in ionic liquid and aqueous acid with thiourea and halides using Fe(III) or HSO5- oxidant', Hydrometallurgy, 98 276-280 (2009) [C1]
DOI10.1016/j.hydromet.2009.05.012
CitationsScopus - 11Web of Science - 9
Co-authorsGeoffrey Lawrance
2009Odell LR, Skopec J, McCluskey A, 'Isolation and identification of unique marker compounds from the Tasmanian poppy Papaver somniferum N. Implications for the identification of illicit heroin of Tasmanian origin (vol 175, pg 202, 2008)', FORENSIC SCIENCE INTERNATIONAL, 183 105-106 (2009) [C3]
DOI10.1016/j.forsciint.2008.10.006Author URL
2009Mann JP, McCluskey A, Atkin R, 'Activity and thermal stability of lysozyme in alkylammonium formate ionic liquids: Influence of cation modification', Green Chemistry, 11 785-792 (2009) [C1]
DOI10.1039/b900021f
CitationsScopus - 59Web of Science - 55
Co-authorsRob Atkin
2008Zhang J, Lawrance GA, Chau N, Robinson PJ, McCluskey A, 'From Spanish fly to room-temperature ionic liquids (RTILs): Synthesis, thermal stability and inhibition of dynamin 1 GTPase by a novel class of RTILs', New Journal of Chemistry, 32 28-36 (2008) [C1]
DOI10.1039/b707092f
CitationsScopus - 20Web of Science - 22
Co-authorsGeoffrey Lawrance
2008Hill TA, Stewart SG, Gordon CP, Ackland SR, Gilbert J, Sauer B, et al., 'Norcantharidin analogues: Synthesis, anticancer activity and protein phosphatase 1 and 2A inhibition', ChemMedChem, 3 1878-1892 (2008) [C1]
DOI10.1002/cmdc.200800192
CitationsScopus - 32Web of Science - 32
Co-authorsJennette Sakoff, Stephen Ackland
2008McCluskey A, Wentrup C, '2-pyridyinitrene from tetrazolo[1,5-a]pyridine and Pyrido[2,3-a][1,2,4]oxadiazol-2-one', JOURNAL OF ORGANIC CHEMISTRY, 73 6265-6267 (2008) [C1]
DOI10.1021/jo800899tAuthor URL
CitationsScopus - 14Web of Science - 14
2008Thaqi A, McCluskey A, Scott JL, 'A mild Boc deprotection and the importance of a free carboxylate', Tetrahedron Letters, 49 6962-6964 (2008) [C1]
DOI10.1016/j.tetlet.2008.09.027
CitationsScopus - 11Web of Science - 9
2008Odell L, Skopec J, McCluskey A, 'Isolation and identification of unique marker compounds from the Tasmanian poppy Papaver somniferum N. Implications for the identification of illicit heroin of Tasmanian origin', Forensic Science International, 175 202-208 (2008) [C1]
DOI10.1016/j.forsciint.2007.07.002
CitationsScopus - 4Web of Science - 5
2007Whitehead JA, Zhang J, Pereira N, McCluskey A, Lawrance GA, 'Application of 1-alkyl-3-methyl-imidazolium ionic liquids in the oxidative leaching of sulphidic copper, gold and silver ores', Hydrometallurgy, 88 109-120 (2007) [C1]
DOI10.1016/j.hydromet.2007.03.009
CitationsScopus - 35Web of Science - 27
Co-authorsGeoffrey Lawrance
2007Qi Y, Evans I, McCluskey A, 'New impurity profiles of recent Australian imported 'ice': Methamphetamine impurity profiling and the identification of (pseudo)ephedrine and Leuckart specific marker compounds', Forensic Science International, 169 173-180 (2007) [C1]
DOI10.1016/j.forsciint.2006.08.016
CitationsScopus - 17Web of Science - 17
2007Hill TA, Stewart SG, Sauer B, Gilbert J, Ackland S, Sakoff JA, McCluskey A, 'Heterocyclic substituted cantharidin and norcantharidin analogues-synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity', Bioorganic and Medicinal Chemistry Letters, 17 3392-3397 (2007) [C1]
DOI10.1016/j.bmcl.2007.03.093
CitationsScopus - 49Web of Science - 45
Co-authorsJennette Sakoff, Stephen Ackland
2007Hill TA, Stewart SG, Ackland S, Gilbert J, Sauer B, Sakoff JA, McCluskey A, 'Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation', Bioorganic and Medicinal Chemistry, 15 6126-6134 (2007) [C1]
DOI10.1016/j.bmc.2007.06.034
CitationsScopus - 51Web of Science - 49
Co-authorsStephen Ackland, Jennette Sakoff
2007Stewart SG, Hill TA, Gilbert J, Ackland S, Sakoff JA, McCluskey A, 'Synthesis and biological evaluation of norcantharidin analogues: Towards PP1 selectivity', Bioorganic and Medicinal Chemistry, 15 7301-7310 (2007) [C1]
DOI10.1016/j.bmc.2007.08.028
CitationsScopus - 33Web of Science - 27
Co-authorsJennette Sakoff, Stephen Ackland
2007Odell L, McCluskey A, Failes TW, Tiekink ERT, 'Crystal and molecular structures of benzyl-(2-chloro-6-methylpyrimidin-4-yl)amine and benzyl-(4-chloro-6-methylpyrimidin-2-yl)amine: Confirmation of computationally predicted restricted rotation', Journal of Chemical Crystallography, 37 817-824 (2007) [C1]
DOI10.1007/s10870-007-9253-2
CitationsScopus - 1Web of Science - 1
2007Hemley CF, McCluskey A, Keller PA, 'Corticotropin releasing hormone - A GPCR drug target', Current Drug Targets, 8 105-115 (2007) [C1]
DOI10.2174/138945007779315542
CitationsScopus - 24Web of Science - 24
2007McCluskey A, Holdsworth CI, Bowyer MC, 'Molecularly imprinted polymers (MIPs): sensing, an explosive new opportunity?', Organic & Biomolecular Chemistry, 5 3233-3244 (2007) [C1]
DOI10.1039/b708660a
CitationsScopus - 48Web of Science - 45
Co-authorsMichael Bowyer, Clovia Holdsworth
2007Booker KM, Bowyer MC, Lennard CJ, Holdsworth CI, McCluskey A, 'Molecularly imprinted polymers and room temperature ionic liquids: Impact of template on polymer morphology', Australian Journal of Chemistry, 60 51-56 (2007) [C1]
DOI10.1071/ch06284
CitationsScopus - 16Web of Science - 15
Co-authorsMichael Bowyer, Clovia Holdsworth
2007Quan A, McGeachie AB, Keating DJ, Van Dam EM, Rusak J, Chau N, et al., 'Myristyl trimethyl ammonium bromide and octadecyl trimethyl ammonium bromide are surface-active small molecule dynamin inhibitors that block endocytosis mediated by dynamin I or dynamin II', Molecular Pharmacology, 72 1425-1439 (2007) [C1]
DOI10.1124/mol.107.034207
CitationsScopus - 51Web of Science - 50
2006Keller PA, McCluskey A, Morgan J, O'Connor SMJ, 'The role of the HPA axis in psychiatric disorders and CRF antagonists as potential treatments', Archiv Der Pharmazie, 339 346-355 (2006) [C1]
DOI10.1002/ardp.200600021
CitationsScopus - 9Web of Science - 13
2006Odell L, Skopec J, McCluskey A, 'A `cold synthesis' of heroin and implications in heroin signature analysis: Utility of trifluoroacetic/acetic anhydride in the acetylation of morphine', Forensic Science International, 164 221-229 (2006) [C1]
DOI10.1016/j.forsciint.2006.02.009
CitationsScopus - 5Web of Science - 3
2006Qi Y, Evans ID, McCluskey A, 'Australian Federal Police seizures of illicit crystalline methamphetamine (`ice') 1998-2002: Impurity analysis', Forensic Science International, 164 201-210 (2006) [C1]
DOI10.1016/j.forsciint.2006.01.010
CitationsScopus - 24Web of Science - 22
2006Booker KM, Bowyer MC, Holdsworth CI, McCluskey A, 'Efficient preparation and improved sensitivity of molecularly imprinted polymers using room temperature ionic liquids', Chemical Communications, 1730-1732 (2006) [C1]
DOI10.1039/b517886j
CitationsScopus - 31Web of Science - 31
Co-authorsClovia Holdsworth, Michael Bowyer
2006Griffith R, Brown MN, McCluskey A, Ashman LK, 'Small molecule inhibitors of protein kinases in cancer - How to overcome resistance', Mini-Reviews in Medicinal Chemistry, 6 1101-1110 (2006) [C1]
DOI10.2174/138955706778560184
CitationsScopus - 5Web of Science - 4
Co-authorsLeonie Ashman
2006Whitehead JA, Lawrence GA, Owen MP, McCluskey A, 'A new route to precious metal recovery and subsequent electrodeposition using ionic liquids', Proceedings - Electrochemical Society, PV 2004-24 901-910 (2006)

Gold extraction from complex sulfidic ore occurs in l-butyl-3- methylimidazolium hydrogen sulfate (bmim+HS4-) ionic liquid in the presence of thiourea in a facile, high yielding (86%), recyclable process. Silver recovery from the ore is also enhanced. Gold recovery from ionic liquid / water environments directly by electrodeposition is described. Changing from aqueous acid to ionic liquid solvent causes a growth mode transition to dendritic growth patterns for deposited gold.

2006Schwarz LJ, Bowyer MC, Holdsworth CI, McCluskey A, 'Synthesis and evaluation of a molecularly imprinted polymer selective to 2,4,6-trichloroanisole', Australian Journal of Chemistry, 59 129-134 (2006) [C1]
DOI10.1071/CH05318
CitationsScopus - 19Web of Science - 18
Co-authorsClovia Holdsworth, Michael Bowyer
2005Holdsworth CI, Bowyer MC, Lennard C, McCluskey A, 'Formulation of cocaine-imprinted polymers utilizing molecular modelling and NMR analysis', Australian Journal of Chemistry, 58 315-320 (2005) [C1]
DOI10.1071/CH04138
CitationsScopus - 24Web of Science - 24
Co-authorsClovia Holdsworth, Michael Bowyer
2005Hill TA, Odell L, Edwards JK, Graham ME, McGeachie AB, Rusak J, et al., 'Small molecule inhibitors of dynamin I GTPase activity: Development of dimeric tyrphostins', Journal of Medicinal Chemistry, 48 7781-7788 (2005) [C1]
DOI10.1021/jm040208l
CitationsScopus - 37Web of Science - 39
2005McCluskey A, Leitch SK, Garner JA, Caden CE, Hill TA, Odell L, Stewart SG, 'BiCl3-mediated opening of epoxides, a facile route to chlorohydrins or amino alcohols: one reagent, two paths', Tetrahedron Letters, 46 8229-8232 (2005) [C1]
DOI10.1016/j.tetlet.2005.09.088
CitationsScopus - 31Web of Science - 30
2005Leitch SK, Addison-Jones J, McCluskey A, 'Regioselective N- and C2-electrophilic substitution of 3-substituted indoles (short communication)', Tetrahedron Letters, 46 2915-2918 (2005) [C1]
DOI10.1016/j.tetlet.2005.02.153
CitationsScopus - 14Web of Science - 13
2004Whitehead JA, Lawrance GA, McCluskey A, 'Analysis of Gold in Solutions Containing Ionic Liquids by Inductively Coupled Plasma Atomic Emission Spectometry', Australian Journal of Chemistry, 57 151-155 (2004) [C1]
DOI10.1071/CH03198
CitationsScopus - 30Web of Science - 30
Co-authorsGeoffrey Lawrance
2004Schwarz LJ, Holdsworth CI, McCluskey A, Bowyer MC, 'Synthesis and Evaluation of a Molecularly Imprinted Polymer Selective to 2,4,6-Trichlorophenol', Australian Journal of Chemistry, 57 759-764 (2004) [C1]
DOI10.1071/CH04004
CitationsScopus - 30Web of Science - 31
Co-authorsMichael Bowyer, Clovia Holdsworth
2004Garner JA, Keller PA, McCluskey A, 'Corticotrophin Releasing Hormone: Chemistry and Recent Developments', Australian Journal of Chemistry, 57 393-407 (2004) [C1]
DOI10.1071/CH03180
CitationsScopus - 3Web of Science - 3
2004Garner JA, Hill TA, Odell L, Keller P, Morgan J, McCluskey A, 'Identification of Aminopyrimidine Regioisomers via Line Broadening Effects in 1H and 13C NMR Spectroscopy', Australian Journal of Chemistry, 57 1079-1083 (2004) [C1]
DOI10.1071/CH03316
CitationsScopus - 1Web of Science - 2
2004Bowyer MC, Gordon CM, Leitch SK, McCluskey A, Ritchie C, 'Indium-Mediated Addition of 4-Bromocrotonic Acid to Aldehydes and Ketones - A Simple, High Yielding Route to Alpha-Allyl-Beta-Hydroxy Carboxylic Acids', Australian Journal of Chemistry: an international journal for chemical science, 57 135-137 (2004) [C1]
DOI10.1071/CH03212
CitationsScopus - 5Web of Science - 4
Co-authorsMichael Bowyer
2004Sakoff JA, Howitt IJ, Ackland S, McCluskey A, 'Serine/threonine protein phosphatase inhibition enhances the effect of thymidylate synthase inhibition', Cancer Chemotherapy and Pharmacology, 53 225-232 (2004) [C1]
DOI10.1007/s00280-003-0730-9
CitationsScopus - 8Web of Science - 7
Co-authorsStephen Ackland, Jennette Sakoff
2004Hart ME, Chamberlin AR, Walkom CC, Sakoff JA, McCluskey A, 'Modified norcantharidins: synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity', Bioorganic & Medicinal Chemistry Letters, 14 1969-1973 (2004) [C1]
DOI10.1016/j.bmcl.2004.01.093
CitationsScopus - 66Web of Science - 64
Co-authorsJennette Sakoff
2004Hill TA, Odell L, Quan A, Abagyan R, Ferguson GN, Robinson PJ, McCluskey A, 'Long chain amines and long chain ammonium salts as novel inhibitors of dynamin GTPase activity', Bioorganic & Medicinal Chemistry Letters, 14 3275-3278 (2004) [C1]
DOI10.1016/j.bmcl.2004.03.096
CitationsScopus - 35Web of Science - 34
2004Sakoff JA, McCluskey A, 'Protein Phosphatase Inhibition: Structure Based Design. Towards New Therapeutic Agents', Current Pharmaceutical Design, 10 1139-1159 (2004) [C1]
DOI10.2174/1381612043452686
CitationsScopus - 46Web of Science - 44
Co-authorsJennette Sakoff
2004McCluskey A, Bowyer MC, 'Synthetic antibodies and the Australian wine industry: A Hunter Valley solution to cork taint?', Australian & New Zealand Grapegrower & Winemaker, 2004 111-115 (2004) [C3]
Co-authorsMichael Bowyer
2004Whitehead JA, Lawrance GA, McCluskey A, ''Green' leaching: recyclable and selective leaching of gold-bearing ore in an ionic liquid', Green Chemistry, 6 313-315 (2004) [C1]
DOI10.1039/b406148a
CitationsScopus - 51Web of Science - 41
Co-authorsGeoffrey Lawrance
2003Correa W, Edwards J, McCluskey A, McKinnon I, Scott JL, 'A thermodynamic investigation of solvent-free reactions', Green Chemistry, 5 30-33 (2003) [C1]
DOI10.1039/b210220j
CitationsScopus - 20Web of Science - 19
2003McCluskey A, Keller PA, Morgan J, Garner JA, 'Synthesis, molecular modeling and biological activity of methyl and thiomethyl substituted pyrimidines as corticotropin releasing hormone type 1 antagonists', Organic and Biomolecular Chemistry, 1 3353-3361 (2003) [C1]
DOI10.1039/b305458f
CitationsScopus - 18Web of Science - 16
2003Ackland S, Bowyer MC, Baldwin ML, Garner JA, Walkom CC, Sakoff JA, McCluskey A, 'Cantharidin analogues: synthesis and evaluation of growth inhibition in a panel of selected tumour cell lines', Bioorganic Chemistry, 31 68-79 (2003) [C1]
DOI10.1016/S0045-2068(02)00524-2
CitationsScopus - 72Web of Science - 61
Co-authorsMichael Bowyer, Stephen Ackland, Jennette Sakoff
2003Leitch SK, McCluskey A, 'A High Yielding One-Pot Synthesis of Allylic-Vinylic Alcohols: The Adducts of Tetraallylstannane and a,?-Unsaturated Carbonyl Compounds', Synlett, - 699-701 (2003) [C1]
DOI10.1055/s-2003-38365
CitationsScopus - 3Web of Science - 3
2002McCluskey A, Sim A, Sakoff J, 'Serine-threonine protein phosphatase inhibitors: Development of potential therapeutic strategies', Journal of Medicinal Chemistry, 45 1151-1175 (2002) [C1]
CitationsScopus - 178Web of Science - 176
Co-authorsJennette Sakoff, Alistair Sim
2002McCluskey A, Robinson P, Hill TA, Scott J, Edwards JK, 'Green chemistry approaches to the Knoevenagel condensation: comparison of ethanol, water and solvent free (dry grind) approaches', Tetrahedron Letters, 43 3117-3120 (2002) [C1]
CitationsScopus - 58Web of Science - 47
2002Judeh Z, Ching C, Bu J, McCluskey A, 'The first Bischler-Napieralski cyclization in a room temperature ionic liquid', Tetrahedron Letters, 43 5089-5091 (2002) [C1]
CitationsScopus - 45Web of Science - 42
2002Gordon CM, Ritchie C, McCluskey A, Stark A, 'Indium- and tin-mediated allylation reactions in ionic liquids.', ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 224 U614-U614 (2002)
Author URL
2002Sakoff J, Ackland S, Baldwin ML, Atherton MA, McCluskey A, 'Anticancer activity and protein phosphatase 1 and 2A inhibition of a new generation of cantharidin analogues', Investigational New Drugs, 20 1-11 (2002) [C1]
CitationsScopus - 62Web of Science - 53
Co-authorsMirella Atherton, Jennette Sakoff, Stephen Ackland
2002McCluskey A, Ackland S, Gardiner E, Walkom CC, Sakoff J, 'The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?', Anti-Cancer Drug Design, 16 291-303 (2002) [C1]
CitationsScopus - 27Web of Science - 22
Co-authorsStephen Ackland, Jennette Sakoff
2002McCluskey A, Atherton MA, Walkom CC, Bowyer M, Sim A, Young D, Sakoff J, 'The first two cantharidin analogues displaying PP1 selectivity', Bioorganic & Medicinal Chemistry Letters, 12 391-393 (2002) [C1]
CitationsScopus - 39Web of Science - 38
Co-authorsMichael Bowyer, Alistair Sim, Jennette Sakoff, Mirella Atherton
2001Lengyel I, Nairn AC, McCluskey A, Toth G, Penke B, Rostas JAP, 'Auto-inhibition of Ca2+/calmodulin-dependent protein kinase II by its ATP-binding domain', Journal of Neurochemistry, 76 1066-1072 (2001) [C1]
CitationsScopus - 10Web of Science - 8
Co-authorsJohn Rostas
2001McCluskey A, Muderawan IW, Muntari, Young DJ, 'A highly atom efficient, solvent promoted addition of tetraallylic, tetraallenic and tetrapropargylic stannanes to carbonyl compounds', Journal of Organic chemistry, 66 7811-7817 (2001) [C1]
CitationsScopus - 26Web of Science - 26
2001McCluskey A, Young DJ, 'Organostannanes and ionic liquids: Toward green chemistry.', ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 221 U564-U564 (2001)
Author URL
2001McCluskey A, Lawrance GA, Owen M, Hamilton IC, 'Ionic liquids: From green chemistry to ore refining.', ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 221 U584-U584 (2001)
Author URL
Co-authorsGeoffrey Lawrance
2001McCluskey A, Walkom CC, Bowyer MC, Ackland SP, Gardiner E, Sakoff JA, 'Cantharimides: A new class of modified cantharidin analogues inhibiting protein phosphatases 1 and 2A', Bioorganic & Medicinal Chemistry Letters, 11 2941-2946 (2001) [C1]
CitationsScopus - 55Web of Science - 55
Co-authorsMichael Bowyer, Jennette Sakoff, Stephen Ackland
2001McCluskey A, Sakoff JA, 'Small molecule inhibitors of serine/threonine protein phosphatases.', Mini reviews in medicinal chemistry, 1 43-55 (2001)

Serine/threonine protein phosphatases have long been ignored as potential therapeutic targets for two reasons, one the biochemical significance of these proteins has not been appreciated and two, many natural protein phosphatase inhibitors are potent toxins and are considered unsuitable for clinical use. This review outlines the biochemical role of this protein family in cancer, cystic fibrosis, immunosuppression and, cardiac and neurological disorders. Particular emphasis is also given to the synthesis of selective small molecule inhibitors and their clinical exploitation.

CitationsScopus - 56
Co-authorsJennette Sakoff
2000McCluskey A, Finn M, Bowman M, Keller P, Smith R, '3,5-Dimethyl-7-hydrazinothiazolo[4,5-d]pyradazine-7-thiol: A corticotrophin releasing hormone type 1 receptor agonist', Australian Journal of Chemistry, 53 905-908 (2000) [C1]
2000McCluskey A, Finn M, Bowman M, Keller PA, Smith R, '2,7-dimethylthiazolo[4,5-d] pyradazine-4-(5H)-thione: a corticotrophin releasing hormone type 1 receptor agonist', Australian journal of chemistry, 905-908 (2000) [C1]
CitationsScopus - 3Web of Science - 2
Co-authorsRoger Smith, Maria Bowman
2000McCluskey A, Garner JA, Caballero S, Young D, 'Tetraallylstannane and Weinreb amides: a simple 'green' route to N-protected homoallylic alcohols and allyl ketones', Tetrahedron Letters, 41 8147-8151 (2000) [C1]
CitationsScopus - 25Web of Science - 22
2000McCluskey A, Atherton MA, Mudgee L, Sim A, Sakoff JA, Quinn R, 'Anhydride modified cantharidin analogues. Is ring opening important in the inhibition of protein phosphatase 2A?', European Journal of Medicinal Chemistry, 35 957-964 (2000) [C1]
CitationsScopus - 41Web of Science - 38
Co-authorsAlistair Sim, Mirella Atherton, Jennette Sakoff
2000Bowyer MC, 'Anhydride Modified Cantharidin Analogues: Synthesis, Inhibition of Protein Phosphatases 1 and 2A and Anticancer Activity', Bioorganic & Medicinal Chemistry Letters, 10 1687-1690 (2000) [C1]
CitationsScopus - 69Web of Science - 69
Co-authorsMichael Bowyer, Alistair Sim, Jennette Sakoff
2000McCluskey A, Elfick LG, Morgan J, Garner JA, Keller P, 'Corticotropin releasing hormone: Therapeutic implications and medicinal chemistry developments', Bioorganic and Medicinal Chemistry., 8 1213-1223 (2000) [C1]
CitationsScopus - 29Web of Science - 30
2000Sakoff JA, McCluskey A, Sims ATR, Stewart JF, Ackland SP, 'A counter intuitive therapy for the treatment of cancer: Inhibition of protein phosphatases 1 and 2A by cantharidin (Spanish Fly) analogues.', CLINICAL CANCER RESEARCH, 6 4495S-4495S (2000)
Author URL
Co-authorsJennette Sakoff, Stephen Ackland
1999Keller PA, Bowman M, Dang KH, Garner JA, Leach SP, Smith R, McCluskey A, 'Pharmacophore development for corticotropin-releasing hormone: new insights into inhibitor activity', Journal of Medicinal Chemistry, 42, No. 13 2351-2357 (1999) [C1]
CitationsScopus - 36Web of Science - 37
Co-authorsRoger Smith, Maria Bowman
1999McCluskey A, Garner JA, Smith R, Leach S, Dang D, Bowman M, Keller P, 'Pharmacophore development for corticotrophin releasing hormone; new insights into inhibitor activity', Journal of Medicinal Chemistry, 42 2351-2357 (1999) [C1]
1999Garner JA, McCluskey A, 'Regiocontrolled amination of dichloropyrimidines in LiC104-Et20 solutions', Heterocyclic Communications, 5, No. 6 503-508 (1999) [C1]
CitationsScopus - 4Web of Science - 4
1999McCluskey A, Garner JA, 'Garner, J, McCluskey, A, "A simple, expedient synthesis of substituted pyrimidines: Aminolysis of dichloropyrimidines in the presence of LiClO4', Heterocyclic Communications, 5 503-508 (1999) [C1]
1999Gordon CM, McCluskey A, 'Ionic liquids: a convenient solvent for environmentally friendly allylation reactions with tetraallylstannane', Chemical Communications, -- 1431-1432 (1999) [C1]
CitationsWeb of Science - 61
1999McCluskey A, 'The allylation of carbonyl (and acetal) compounds by tetraallylstannane', Green Chemistry, -- 167-168 (1999) [C1]
1999McCluskey A, 'Water promoted organic chemistry. The allylation of carbonyl (and acetal) compounds by tetraallylstannane', Green Chemistry, 1 161-162 (1999) [C1]
CitationsScopus - 11Web of Science - 11
1998McCluskey A, Ying L, Camp D, Moni R, Quinn R, 'Diimidazo[1,2-C;4',5'-E] Pyrimidines N6-N1 Conformationally Restricted Andenosines', Bioorganic and Medicinal Chemistry Letters, 8 695-698 (1998) [C1]
CitationsWeb of Science - 4
1998McCluskey A, Dunkin I, 'Tetrachlorocyclopentadienone O-oxide, A Facile Oxygen Transfer Reagent, Further Evidence for the Disproportionation of Cycloalkoky Radicals', Bulletin of the Chemical Society of Japan, 71 1397-1400 (1998) [C1]
CitationsScopus - 1
1998McCluskey A, Wayan Muderawan I, Muntari J, Young D, 'Solvent Assisted Addition of Tetraallylic, Tetraallenic and Tetraaproparagylic Stannanes to Aldehydes and Acetals', SynLett, -- 909-912 (1998) [C1]
CitationsScopus - 9Web of Science - 15
1997Cokley TM, Harvey PJ, Marshall RL, McCluskey A, Young DJ, 'Solvent-mediated allylation of carbonyl compounds with allylic stannanes', JOURNAL OF ORGANIC CHEMISTRY, 62 1961-1964 (1997)
DOI10.1021/jo962332lAuthor URL
CitationsScopus - 47Web of Science - 49
1997McCluskey A, Mayer DM, Young DJ, 'A simple one pot procedure for the generation of homoallylic alcohols from acetals and amino acetals', TETRAHEDRON LETTERS, 38 5217-5218 (1997)
DOI10.1016/S0040-4039(97)01106-4Author URL
CitationsScopus - 28Web of Science - 30
1997Cokley TM, Isaacs NS, McCluskey A, Young DJ, 'High pressure allylstannane addition to alpha-amino aldehydes: Syn diastereoselectivity in the absence of chelation control.', MAIN GROUP METAL CHEMISTRY, 20 581-582 (1997)
Author URL
CitationsScopus - 8Web of Science - 7
1996Cokley TM, Marshall RL, McCluskey A, Young DJ, 'The solvent promoted addition of tetraallyltin to aldehydes: A convenient and chemoselective allylation procedure', TETRAHEDRON LETTERS, 37 1905-1908 (1996)
DOI10.1016/0040-4039(96)00149-9Author URL
CitationsWeb of Science - 25
1996McCluskey A, Taylor C, Quinn RJ, Suganuma M, Fujiki H, 'Inhibition of protein phosphatase 2A by cantharidin analogues.', BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 6 1025-1028 (1996)
DOI10.1016/0960-894X(96)00166-7Author URL
CitationsWeb of Science - 38
1995DUNKIN IR, MCCLUSKEY A, 'TETRACHLOROCYCLOPENTADIENONE O-OXIDE, A FACILE OXYGEN-ATOM TRANSFER REAGENT - THE OXIDATION OF CYCLOHEXENE', JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY A-CHEMISTRY, 89 157-161 (1995)
DOI10.1016/1010-6030(94)04022-TAuthor URL
CitationsWeb of Science - 1
1995MCCLUSKEY A, DUNKIN IR, 'SUPPRESSION OF THE WOLFF REARRANGEMENT OF AN UNSTRAINED ALPHA-CARBONYL CARBENE BY CO AND O-2 IN LOW-TEMPERATURE MATRICES', AUSTRALIAN JOURNAL OF CHEMISTRY, 48 1107-1116 (1995)
DOI10.1071/CH9951107Author URL
CitationsWeb of Science - 4
1995BLANCH RJ, MCCLUSKEY A, 'XCN (X=CL, BR AND I) - A NOVEL SOURCE OF ISOCYANOGEN', CHEMICAL PHYSICS LETTERS, 241 116-120 (1995)
DOI10.1016/0009-2614(95)00595-UAuthor URL
CitationsWeb of Science - 7
1994DUNKIN IR, MCCLUSKEY A, 'A SPECTROSCOPIC STUDY OF THE REACTION OF THE CARBENE, TETRABROMOCYCLOPENTADIENYLIDENE, WITH O2 IN LOW-TEMPERATURE MATRICES', SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY, 50 151-160 (1994)
DOI10.1016/0584-8539(94)80123-1Author URL
CitationsWeb of Science - 2
1994DUNKIN IR, MCCLUSKEY A, 'CARBONYL CYANIDE O-OXIDE, THE ADDUCT OF DICYANOMETHYLENE AND DIOXYGEN IN ARGON MATRICES AT 12-K', SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY, 50 209-218 (1994)
DOI10.1016/0584-8539(94)80048-0Author URL
CitationsWeb of Science - 9
1993DUNKIN IR, MCCLUSKEY A, 'TETRABROMOCYCLOPENTADIENYLIDENE - GENERATION AND REACTION WITH CO IN LOW-TEMPERATURE MATRICES', SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY, 49 1179-1185 (1993)
DOI10.1016/0584-8539(93)80077-NAuthor URL
CitationsWeb of Science - 4
1993DUNKIN IR, MCCLUSKEY A, 'TETRACHLOROCYCLOPENTADIENONE O-OXIDE, A FACILE OXYGEN-ATOM TRANSFER REAGENT - THE OXIDATION OF CYCLOHEXANE', JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY A-CHEMISTRY, 74 159-164 (1993)
DOI10.1016/1010-6030(93)80112-MAuthor URL
CitationsWeb of Science - 4
1986DUNKIN IR, BELL GA, MCCLEOD FG, MCCLUSKEY A, 'AN INFRARED STUDY OF THE FORMATION AND PHOTOCHEMICAL DECOMPOSITION OF TETRACHLOROCYCLOPENTADIENONE O-OXIDE IN LOW-TEMPERATURE MATRICES', SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY, 42 567-574 (1986)
Author URL
CitationsWeb of Science - 14
Show 165 more journal articles

Review (1 outputs)

YearCitationAltmetricsLink
2003Keller PA, Kirkwood KL, Morgan J, Westcott S, McCluskey A, 'The prevention of preterm labour - corticotrophin releasing hormone type 1 receptors as a target for drug design and development', Med. Chem. (2003) [D2]

Conference (23 outputs)

YearCitationAltmetricsLink
2014Sakoff J, Gilbert J, McCluskey A, 'Small molecules selectively targeting breast cancer cells', EUROPEAN JOURNAL OF CANCER, European Org Res & Treatment Canc, Barcelona, SPAIN (2014) [E3]
Author URL
Co-authorsJennette Sakoff
2014Gilbert J, Dun MD, De Iuliis GN, McCluskey A, Sakoff JA, 'SELECTIVELY TARGETING BREAST CANCER CELLS VIA CHECKPOINT ACTIVATION', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
Co-authorsMatt Dun, Geoffry DeiuliIs, Jennette Sakoff
2014Gilbert J, McCluskey A, Sakoff JA, 'ENHANCING RADIATION EFFECTS FOR THE TREATMENT OF BRAIN CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
Co-authorsJennette Sakoff
2013Sakoff JA, Gilbert J, Tarleton M, Robertson M, McCluskey A, 'New small molecules targeting breast cancer', INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2013) [E3]
Author URL
Co-authorsJennette Sakoff
2012Harper CB, Martin S, Nguyen TN, McCluskey A, Robinson PJ, Meunier FA, 'Role of the presynaptic plasma membrane in sorting local from retrograde vesicular trafficking pathways', Abstracts. Australian Neuroscience Society 32nd Annual Meeting, Gold Coast, Queensland (2012) [E3]
2012Stehn JR, Haass NK, Bonello T, Desouza M, Kottyan G, Treutlein H, et al., 'Developing chemotherapeutics which selectively disable the actin cytoskeleton of tumor cells', Experimental Dermatology, Marburg, Germany (2012) [E3]
2011Stehn JR, Haass NK, Desouza M, Sequeira VB, Treutlein H, Zeng J, et al., 'Developing chemotherapeutics which disable the actin cytoskeleton of melanoma cells', Pigment Cell & Melanoma Research, Tampa, FL (2011) [E3]
DOI10.1111/j.1755-148X.2011.00909.x
2011Robinson KM, McCluskey A, Attalla MI, 'The effect of molecular structural variations on the CO2 absorption characteristics of heterocyclic diamines for amine-based post combustion CO2 capture', Chemeca 2011: Engineering a Better World, Sydney (2011) [E1]
2010Joshi S, Gaddipatti S, Gilbert J, Smith CM, Gordon CP, Sakoff JA, et al., 'Dynamin inhibition: A new therapeutic approach for the treatment of cancer', AACR 101st Annual Meeting 2010. Abstracts, Washington, DC (2010) [E3]
Co-authorsJennette Sakoff
2010Gunning PW, Hook J, Schevzov G, Desouza M, Creed S, McCluskey A, et al., 'Actin filaments containing tropomyosin Tm5NM1/2 perform essential functions as revealed by gene knockouts and anti-Tm drugs', The American Society for Cell Biology 50th Annual Meeting Abstracts, Phildelphia, PA (2010) [E3]
2010McCluskey A, Robinson PJ, 'From dyngoes to dynasores: Selective dynamin inhibitors as novel antiepileptic agents', Australasian Society of Clinical and Experimental Pharmacology and Toxicology (ASCEPT) Annual Scientific Meeting, Melbourne, Vic (2010) [E3]
2010Bonello T, Stehn J, Schevzov G, Coombes J, McCluskey A, Haass N, et al., 'Targeting the tropomyosin isoform TM5NM1 impairs tumour survival, proliferation and migration', OzBio 2010: The Molecules of Life - from Discovery to Biotechnology. Poster Abstracts, Melbourne, Australia (2010) [E3]
2010Chircop M, Perera S, Ma MPC, Lau H, Gilbert J, Jones NC, et al., 'Dynole 34-2 is a potent inhibitor of dynamin that induces cell death following cytokinesis failure and suppresses glioblastoma tumour growth in vivo', OzBio 2010: The Molecules of Life - from Discovery to Biotechnology. Poster Abstracts, Melbourne, Australia (2010) [E3]
Co-authorsJennette Sakoff
2010Mariana A, Hill TA, McGeachie AB, Chau N, Daniel JA, Gorgani NN, et al., 'Towards isoform-selective dynamin inhibitors', OzBio 2010: The Molecules of Life - from Discovery to Biotechnology. Poster Abstracts, Melbourne, Australia (2010) [E3]
2010Stehn J, Schevzov G, Bonello T, McCluskey A, Haass N, Palmer S, et al., 'Tropomyosin Tm5NM1: A novel target for cancer therapy', EJC Supplements, Berlin, Germany (2010) [E3]
2009Robinson PJ, McCluskey A, 'Dynamin inhibitors reduce synaptic transmission and are novel anti-epileptic drugs', Journal of Neurochemistry, Beijing, China (2009) [E3]
2008Bajsa J, Sahu R, McCluskey A, Duke SO, Tekwani BL, 'Antimalarial activity of cantharidin analogs: potential serine/threonine protein phosphatase inhibitors', Planta Medica, Oxford, MI (2008) [E3]
DOI10.1055/s-2008-1075251
CitationsWeb of Science - 1
2008Wright A, McCluskey A, Macgregor K, Guenther J, 'Potential ecological role, chemistry and molecular modelling studies of secondary metabolites isolated from the tropical marine sponge Cymbastela hooperi', Planta Medica, Athens, Greece (2008) [E3]
CitationsWeb of Science - 1
2007Chau N, Quan A, Hill TA, McCluskey A, Robinson PJ, 'The apparent potency of dynamin GTPase inhibitors is dependent on dynamin concentration: a new colorimetric assay (Poster)', 7th IBRO 2007 World Congress of Neuroscience Program, Melbourne (2007) [E3]
2007McGeachie AB, Odell L, Hill TA, Quan A, Chau N, Graham ME, et al., 'Analogues of Bis-T-22 potently inhibit endocytosis (Poster)', 7th IBRO 2007 World Congress of Neuroscience Program, Melbourne (2007) [E3]
2007Quan A, McGeachie AB, Van Dam EM, Chau N, McCluskey A, Cousin MA, Robinson PJ, 'Mitmab is a surface-active dynamin inhibitor that blocks dynamin i or dynamin ii mediated endocytosis (Poster)', 7th IBRO 2007 World Congress of Neuroscience Program, Melbourne (2007) [E3]
2007Stehn JR, Butler T, Winlaw D, McCluskey A, Gunning P, 'Tropomyosin containing actin filaments as cancer-specific targets', AACR Meeting Abstracts Online (Abstracts of the 98th AACR Annual Meeting), Los Angeles (2007) [E3]
2002Sakoff JA, Ackland SP, Garg MB, Walkom CC, McCluskey A, 'Protein phosphatase 2A, a novel and unexplored anticancer target', EUROPEAN JOURNAL OF CANCER, FRANKFURT, GERMANY (2002)
Author URL
Co-authorsStephen Ackland, Jennette Sakoff
Show 20 more conferences

Patent (1 outputs)

YearCitationAltmetricsLink
2005McCluskey A, Robinson PJ, Hill TA, Methods and agents for inhibiting dynamic-dependent endocytosis (2005) [I2]
Edit

Grants and Funding

Summary

Number of grants97
Total funding$17,484,210

Click on a grant title below to expand the full details for that specific grant.


20145 grants / $1,178,952

Dual purpose contraception $658,952

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamLaureate Professor John Aitken, Professor Adam McCluskey, Professor Kenneth Beagley
SchemeProject Grant
RoleInvestigator
Funding Start2014
Funding Finish2014
GNoG1300304
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Pushing The Boundaries Of Flow Chemistry - Towards New Anti-Viral Agents$430,000

Funding body: ARC (Australian Research Council)

Funding bodyARC (Australian Research Council)
Project TeamProfessor Adam McCluskey, Professor Volker Haucke
SchemeDiscovery Projects
RoleLead
Funding Start2014
Funding Finish2014
GNoG1300160
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Characterisation of a new class of antimicrobial agent for multidrug-resistant infections$45,000

Funding body: ARC (Australian Research Council)

Funding bodyARC (Australian Research Council)
Project TeamDr Darren Trott, Professor Adam McCluskey, Mr Stephen Page
SchemeLinkage Projects
RoleLead
Funding Start2014
Funding Finish2014
GNoG1401198
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Enhancing radiation effects for the treatment of brain cancer $25,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Jennette Sakoff, Dr JAYNE Gilbert, Professor Adam McCluskey
SchemeProject Grant
RoleInvestigator
Funding Start2014
Funding Finish2014
GNoG1301412
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

The role of dynamin is spermatogenesis and sperm-oocyte interactions$20,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamAssociate Professor Brett Nixon, Professor Eileen McLaughlin, Professor Adam McCluskey
SchemeNear Miss Grant
RoleInvestigator
Funding Start2014
Funding Finish2014
GNoG1301400
Type Of FundingInternal
CategoryINTE
UONY

201310 grants / $564,141

Advanced Stopped Flow - Electron Paramagnetic Resonance Apparatus for Measurement of Short-Lived Free Radicals in Engineering, Science and Medicine$180,000

Funding body: ARC (Australian Research Council)

Funding bodyARC (Australian Research Council)
Project TeamConjoint Professor Bogdan Dlugogorski, Professor Adam McCluskey, Laureate Professor John Aitken, Professor Paul Dastoor, Professor Scott Donne
SchemeLinkage Infrastructure Equipment & Facilities (LIEF)
RoleInvestigator
Funding Start2013
Funding Finish2013
GNoG1200569
Type Of FundingScheme excluded from IGS
CategoryEXCL
UONY

Advanced Stopped Flow - Electron Paramagnetic Resonance Apparatus for Measurement of Short-Lived Free Radicals in Engineering, Science and Medicine$175,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamConjoint Professor Bogdan Dlugogorski, Laureate Professor John Aitken, Professor Paul Dastoor, Professor Scott Donne, Professor Adam McCluskey
SchemeEquipment Grant
RoleInvestigator
Funding Start2013
Funding Finish2013
GNoG1200186
Type Of FundingInternal
CategoryINTE
UONY

Multi-Centre Screening and Development Platform for Pre-Clinical Drugs for Glioblastoma$101,612

Funding body: Cancer Council NSW

Funding bodyCancer Council NSW
Project TeamProfessor Phillip Robinson, Ms Megan Chircop, Professor Roger Reddel, Professor Adam McCluskey, Dr Jennette Sakoff
SchemeResearch Grant
RoleLead
Funding Start2013
Funding Finish2013
GNoG1300989
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Central Contribution to Faculty Peer Review - FSIT$33,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Adam McCluskey
SchemeSpecial Project Grant
RoleLead
Funding Start2013
Funding Finish2013
GNoG1301330
Type Of FundingInternal
CategoryINTE
UONY

New Drugs to Kill Superbugs$13,000

Funding body: University of Newcastle - Faculty of Science & IT

Funding bodyUniversity of Newcastle - Faculty of Science & IT
Project TeamProfessor Peter Lewis, Professor Adam McCluskey, Doctor Chris Gordon, Doctor Joey Ambrus
SchemeStrategic Small Grant
RoleInvestigator
Funding Start2013
Funding Finish2013
GNoG1401065
Type Of FundingInternal
CategoryINTE
UONY

Dynamin - role in sperm oocyte interaction$10,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Eileen McLaughlin, Associate Professor Brett Nixon, Professor Adam McCluskey
SchemeNear Miss Grant
RoleInvestigator
Funding Start2013
Funding Finish2013
GNoG1300483
Type Of FundingInternal
CategoryINTE
UONY

Dynamin - role in sperm oocyte interaction$10,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamProfessor Eileen McLaughlin, Associate Professor Brett Nixon, Professor Adam McCluskey
SchemeNear Miss
RoleInvestigator
Funding Start2013
Funding Finish2013
GNoG1300700
Type Of FundingExternal
CategoryEXTE
UONY

Faculty Visiting Fellowship 2013$3,529

Funding body: University of Newcastle - Faculty of Science & IT

Funding bodyUniversity of Newcastle - Faculty of Science & IT
Project TeamProfessor Adam McCluskey
SchemeVisiting Fellowship
RoleLead
Funding Start2013
Funding Finish2013
GNoG1401142
Type Of FundingInternal
CategoryINTE
UONY

2014 ARC/NHMRC Fellowship External Applicant Support - FSIT$3,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Adam McCluskey, Dr Ali Eshragh
SchemeSpecial Project Grant
RoleLead
Funding Start2013
Funding Finish2013
GNoG1301076
Type Of FundingInternal
CategoryINTE
UONY

20126 grants / $743,610

Mechanism Of Action Of Dynamin Ring Stabilizer Compounds Controlling The Actin Cytoskeleton $318,510

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamProfessor Phillip Robinson, Professor Adam McCluskey
SchemeProject Grant
RoleLead
Funding Start2012
Funding Finish2012
GNoG1101104
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

The role of clathrin in the spindle assembly checkpoint and as an anticancer target$245,100

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamMs Megan Chircop, Professor Adam McCluskey, Professor Phillip Robinson, Doctor Jennette Sakoff
SchemeProject Grant
RoleLead
Funding Start2012
Funding Finish2012
GNoG1101106
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Bioaffinity mass spectrometry infrastructure to identify small molecules binding to therapeutic targets$125,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Ronald Quinn, Associate Professor Sally-Ann Poulsen, Professor Ian Charles, Professor Adam McCluskey, Associate Professor Elizabeth Harry, Professor Johnson Mak
SchemeEquipment Grant
RoleLead
Funding Start2012
Funding Finish2012
GNoG1100742
Type Of FundingInternal
CategoryINTE
UONY

Identification of a novel target for the treatment of hormone positive breast cancer$30,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Jennette Sakoff, Dr JAYNE Gilbert, Professor Adam McCluskey
SchemeBreast Cancer Project Grant
RoleInvestigator
Funding Start2012
Funding Finish2012
GNoG1200716
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

The role of clathrin in the spindle assembly checkpoint and as an anticancer target$15,000

Funding body: NSW Trade & Investment

Funding bodyNSW Trade & Investment
Project TeamProfessor Adam McCluskey, Doctor Jennette Sakoff
SchemeTechVouchers Program
RoleLead
Funding Start2012
Funding Finish2012
GNoG1200796
Type Of FundingOther Public Sector - State
Category2OPS
UONY

Ultrasonic Homogenizer System and -80 ºC Freezers for chemical and biological sample storage$10,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamProfessor Adam McCluskey, Professor Eileen McLaughlin, Professor Peter Lewis, Ms Belinda Nixon, Doctor Shaun Roman, Doctor Jennette Sakoff, Doctor Ian Grainge
SchemeEquipment Grant
RoleLead
Funding Start2012
Funding Finish2012
GNoG1100986
Type Of FundingOther Public Sector - Commonwealth
Category2OPC
UONY

201112 grants / $3,475,731

Chemical principles underpinning a spermostatic-microbiostatic agent capable of preventing pregnancy and the spread of sexually transmitted disease$735,000

Funding body: ARC (Australian Research Council)

Funding bodyARC (Australian Research Council)
Project TeamLaureate Professor John Aitken, Doctor Mark Baker, Professor Kenneth Beagley, Professor Adam McCluskey
SchemeDiscovery Projects
RoleInvestigator
Funding Start2011
Funding Finish2011
GNoG1000173
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Development of pthaladyn-based dynamin I-selective inhibitors for treatment of epilepsy$544,831

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamProfessor Adam McCluskey, Professor Phillip Robinson, Professor Terence O'Brien, Ms Megan Chircop, Doctor Jennette Sakoff
SchemeDevelopment Grants
RoleLead
Funding Start2011
Funding Finish2011
GNoG1000740
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Establishment of a comprehensive regional biophysical analysis facility $500,000

Funding body: ARC (Australian Research Council)

Funding bodyARC (Australian Research Council)
Project TeamProfessor Peter Lewis, Professor Nicholas Dixon, Professor Eileen McLaughlin, Professor Adam McCluskey, Associate Professor Aaron Oakley, Laureate Professor Paul Foster, Laureate Professor John Aitken, Associate Professor Jennifer Beck, Dr Michael Kelso, Professor Graham Nicholson, Associate Professor Elizabeth Harry, Professor Ian Charles, Associate Professor Steven Djordjevic
SchemeLinkage Infrastructure Equipment & Facilities (LIEF)
RoleInvestigator
Funding Start2011
Funding Finish2011
GNoG1000630
Type Of FundingScheme excluded from IGS
CategoryEXCL
UONY

Chemical Biology$444,961

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Adam McCluskey, Doctor Warwick Belcher, Doctor Ian Grainge, Professor Christopher Grof, Professor Peter Lewis, Professor Eileen McLaughlin, Doctor Shaun Roman, Conjoint Professor Ray Rose, Doctor Jennette Sakoff, Doctor Nikki Verrills
SchemePriority Research Centre
RoleLead
Funding Start2011
Funding Finish2011
GNoG1100052
Type Of FundingInternal
CategoryINTE
UONY

Sulfonadyn-based dynamin I-specific inhibitors and epilepsy$403,931

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamProfessor Adam McCluskey, Professor Phillip Robinson
SchemeProject Grant
RoleLead
Funding Start2011
Funding Finish2011
GNoG1100148
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Characterisation of a new class of antimicrobial agent for multidrug-resistant infections$257,250

Funding body: Neoculi Pty Ltd

Funding bodyNeoculi Pty Ltd
Project TeamDr Darren Trott, Professor Adam McCluskey, Mr Stephen Page
SchemeLinkage Projects Partner funding
RoleLead
Funding Start2011
Funding Finish2011
GNoG1100918
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Establishment of a comprehensive regional biophysical analysis facility $230,000

Funding body: ARC (Australian Research Council)

Funding bodyARC (Australian Research Council)
Project TeamProfessor Peter Lewis, Professor Nicholas Dixon, Professor Eileen McLaughlin, Professor Adam McCluskey, Associate Professor Aaron Oakley, Laureate Professor Paul Foster, Laureate Professor John Aitken, Associate Professor Jennifer Beck, Dr Michael Kelso, Professor Graham Nicholson, Associate Professor Elizabeth Harry, Professor Ian Charles, Associate Professor Steven Djordjevic
SchemeLinkage Infrastructure Equipment & Facilities (LIEF) Partner funding
RoleInvestigator
Funding Start2011
Funding Finish2011
GNoG1100484
Type Of FundingScheme excluded from IGS
CategoryEXCL
UONY

Characterisation of a new class of antimicrobial agent for multidrug-resistant infections$214,000

Funding body: ARC (Australian Research Council)

Funding bodyARC (Australian Research Council)
Project TeamDr Darren Trott, Professor Adam McCluskey, Mr Stephen Page
SchemeLinkage Projects
RoleLead
Funding Start2011
Funding Finish2011
GNoG1100855
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Dynamin as a new drug target for the treatment of glioblastoma$96,000

Funding body: Cancer Council NSW

Funding bodyCancer Council NSW
Project TeamProfessor Adam McCluskey
SchemeResearch Program
RoleLead
Funding Start2011
Funding Finish2011
GNoG1100021
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Development of clathrin inhibitors as novel endocytosis inhibitors$25,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Adam McCluskey
SchemeNear Miss Grant
RoleLead
Funding Start2011
Funding Finish2011
GNoG1001050
Type Of FundingInternal
CategoryINTE
UONY

Eppendorf mastercycler pro with thermomixer comfort and 5430R centrifuge$15,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamProfessor Eileen McLaughlin, Professor Peter Lewis, Professor Adam McCluskey, Conjoint Professor Keith Jones, Associate Professor Brett Nixon, Doctor Shaun Roman, Doctor Jennette Sakoff, Doctor Ian Grainge, Doctor Janet Holt, Doctor Xiao Yang
SchemeEquipment Grant
RoleInvestigator
Funding Start2011
Funding Finish2011
GNoG1100028
Type Of FundingOther Public Sector - Commonwealth
Category2OPC
UONY

Restocking the Cupboard - Next generation Antibiotics$9,758

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Adam McCluskey
SchemeLinkage Pilot Research Grant
RoleLead
Funding Start2011
Funding Finish2011
GNoG1100043
Type Of FundingInternal
CategoryINTE
UONY

20109 grants / $3,617,461

Australian Cancer Research Foundation Cancer Research Grant$1,012,636

Funding body: Australian Cancer Research Foundation

Funding bodyAustralian Cancer Research Foundation
Project TeamProfessor Adam McCluskey
SchemeCancer Research Grant
RoleLead
Funding Start2010
Funding Finish2010
GNoG1000006
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Development of a humane non-surgical sterilization method for domestic animals$1,006,825

Funding body: Found Animals Foundation Inc

Funding bodyFound Animals Foundation Inc
Project TeamLaureate Professor John Aitken, Professor Eileen McLaughlin, Professor Adam McCluskey
SchemeMichelson Grants in Reproductive Biology
RoleInvestigator
Funding Start2010
Funding Finish2010
GNoG0900113
Type Of FundingInternational - Competitive
Category3IFA
UONY

An Integrated LC-MS-NMR facility for Applications in Proteomics and Organic Chemistry$500,000

Funding body: ARC (Australian Research Council)

Funding bodyARC (Australian Research Council)
Project TeamProfessor Adam McCluskey, Laureate Professor John Aitken, Professor Paul Dastoor, Professor Phillip Robinson, Professor Eileen McLaughlin, Emeritus Professor Geoffrey Lawrance, Professor Marcel Maeder, Professor Hugh Dunstan, Doctor Shaun Roman, Professor Rob Atkin, Doctor Clovia Holdsworth, Doctor Mark Baker, Doctor Nikki Verrills, Professor Gottfried Otting, Associate Professor Brett Nixon, Doctor Xiaojing Zhou, Ms Megan Chircop, Doctor Warwick Belcher
SchemeLinkage Infrastructure Equipment & Facilities (LIEF)
RoleLead
Funding Start2010
Funding Finish2010
GNoG0190402
Type Of FundingScheme excluded from IGS
CategoryEXCL
UONY

Streamlining the dynamin epilepsy drug pipeline$438,000

Funding body: ARC (Australian Research Council)

Funding bodyARC (Australian Research Council)
Project TeamProfessor Adam McCluskey, Professor Phillip Robinson, Associate Professor Martin Larsen
SchemeDiscovery Projects
RoleLead
Funding Start2010
Funding Finish2010
GNoG0190040
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

The 2009 Ramaciotti Major Initiative Biomedical Research Award$300,000

Funding body: Ramaciotti Foundations

Funding bodyRamaciotti Foundations
Project TeamProfessor Adam McCluskey
SchemeMajor Initiative for Biomedical Research (Defunct)
RoleLead
Funding Start2010
Funding Finish2010
GNoG1000005
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

An Integrated LC-MS-NMR facility for Applications in Proteomics and Organic Chemistry$280,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Adam McCluskey, Laureate Professor John Aitken, Professor Paul Dastoor, Professor Phillip Robinson, Professor Eileen McLaughlin, Emeritus Professor Geoffrey Lawrance, Professor Marcel Maeder, Professor Hugh Dunstan, Doctor Shaun Roman, Professor Rob Atkin, Doctor Clovia Holdsworth, Doctor Mark Baker, Doctor Nikki Verrills, Professor Gottfried Otting, Associate Professor Brett Nixon, Doctor Xiaojing Zhou, Ms Megan Chircop, Doctor Warwick Belcher
SchemeEquipment Grant
RoleLead
Funding Start2010
Funding Finish2010
GNoG1000873
Type Of FundingInternal
CategoryINTE
UONY

Waters, Ultra high performance liquid chromatography system (nano-Aquity) $30,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamDoctor Mark Baker, Laureate Professor John Aitken, Professor Adam McCluskey, Associate Professor Brett Nixon, Emeritus Professor John Rostas, Professor Eileen McLaughlin
SchemeEquipment Grant
RoleInvestigator
Funding Start2010
Funding Finish2010
GNoG1000051
Type Of FundingOther Public Sector - Commonwealth
Category2OPC
UONY

The design of novel, affinity-based technology to specifically isolate phosphotyrosine-containing pedtides$25,000

Funding body: Hunter Children`s Research Foundation

Funding bodyHunter Children`s Research Foundation
Project TeamDoctor Mark Baker, Professor Adam McCluskey
SchemeResearch Grant
RoleInvestigator
Funding Start2010
Funding Finish2010
GNoG0900191
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

Centre for Kinomics$25,000

Funding body: John Morris Scientific Pty Ltd

Funding bodyJohn Morris Scientific Pty Ltd
Project TeamProfessor Adam McCluskey
SchemeResearch Grant
RoleLead
Funding Start2010
Funding Finish2010
GNoG1000614
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

20096 grants / $1,124,582

Development of dynamin inhibitors as novel therapies for epilepsy$306,001

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamProfessor Adam McCluskey
SchemeProject Grant
RoleLead
Funding Start2009
Funding Finish2009
GNoG0190116
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Preclinical new chemical entities as novel anti-epileptic drugs targeting dynamin$132,924

Funding body: Epilepsy Foundation of America

Funding bodyEpilepsy Foundation of America
Project TeamProfessor Adam McCluskey
SchemeNew Therapy Grants Program
RoleLead
Funding Start2009
Funding Finish2009
GNoG1000613
Type Of FundingInternational - Competitive
Category3IFA
UONY

Dynamin as a new drug target for he treatment of glioblastoma$74,457

Funding body: James S. McDonnell Foundation

Funding bodyJames S. McDonnell Foundation
Project TeamProfessor Adam McCluskey, Ms Megan Chircop
SchemeResearch Award
RoleLead
Funding Start2009
Funding Finish2009
GNoG0190466
Type Of FundingInternational - Non Competitive
Category3IFB
UONY

Development of novel anti-epileptic drugs targeting vesicular endocytosis$66,200

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamProfessor Adam McCluskey
SchemeDevelopment Grants
RoleLead
Funding Start2009
Funding Finish2009
GNoG0190117
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

20085 grants / $3,041,290

HMRI Cancer Research Program - MRSP Infrastructure$1,031,290

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamConjoint Professor Stephen Ackland, Emeritus Professor Leonie Ashman, Professor John Forbes, Conjoint Professor Jim Denham, Conjoint Professor Peter Hersey, Professor Gordon Burns, Professor Adam McCluskey, Doctor Nikki Verrills
SchemeNSW MRSP Infrastructure Grant
RoleInvestigator
Funding Start2008
Funding Finish2008
GNoG0188622
Type Of FundingOther Public Sector - State
Category2OPS
UONY

Integrated surface fabrication and characterisation laboratory$750,000

Funding body: ARC (Australian Research Council)

Funding bodyARC (Australian Research Council)
Project TeamProfessor Paul Dastoor, Professor John O'Connor, Professor Bruce King, Professor Adam McCluskey, Doctor Warwick Belcher, Professor Catherine Stampfl, Dr Jeffrey Reimers, Assoc. Prof Alexander Hamilton, Dr Adam Micolich, Doctor Chris Fell, Dr Scott Watkins, Dr Mark Bown, Dr Anton Stampfl, Dr Peter Evans
SchemeLinkage Infrastructure Equipment & Facilities (LIEF)
RoleInvestigator
Funding Start2008
Funding Finish2008
GNoG0187931
Type Of FundingScheme excluded from IGS
CategoryEXCL
UONY

The discovery and validation of novel drug classes against parasites of major economic importance$670,000

Funding body: ARC (Australian Research Council)

Funding bodyARC (Australian Research Council)
Project TeamProfessor Adam McCluskey, Professor Robin Gasser, Dr Jennette Sakoff
SchemeLinkage Projects
RoleLead
Funding Start2008
Funding Finish2008
GNoG0187815
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Partner contributions for Integrated surface fabrication and characterisation laboratory$320,000

Funding body: ARC (Australian Research Council)

Funding bodyARC (Australian Research Council)
Project TeamProfessor Paul Dastoor, Professor John O'Connor, Professor Bruce King, Professor Adam McCluskey, Doctor Warwick Belcher, Professor Catherine Stampfl, Dr Jeffrey Reimers, Assoc. Prof Alexander Hamilton, Dr Adam Micolich, Doctor Chris Fell, Dr Scott Watkins, Dr Mark Bown, Dr Anton Stampfl, Dr Peter Evans
SchemeLinkage Infrastructure Equipment & Facilities (LIEF) Partner funding
RoleInvestigator
Funding Start2008
Funding Finish2008
GNoG0189562
Type Of FundingScheme excluded from IGS
CategoryEXCL
UONY

The discovery and validation of novel drug classes against parasites of major economic importance$270,000

Funding body: Genetic Technologies Limited

Funding bodyGenetic Technologies Limited
Project TeamProfessor Adam McCluskey, Professor Robin Gasser, Dr Jennette Sakoff
SchemeLinkage Projects Partner funding
RoleLead
Funding Start2008
Funding Finish2008
GNoG0188378
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

20074 grants / $693,942

Chemical listening devices: Novel sensors targeting the clandestine manufacture and transport of illicit drugs and explosives$378,942

Funding body: ARC (Australian Research Council)

Funding bodyARC (Australian Research Council)
Project TeamProfessor Adam McCluskey, Associate Professor Michael Bowyer, Doctor Clovia Holdsworth, Professor Christopher Lennard
SchemeLinkage Projects
RoleLead
Funding Start2007
Funding Finish2007
GNoG0186611
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Chemical listening devices: Novel sensors targeting the clandestine manufacture and transport of illicit drugs and explosives$105,000

Funding body: Australian Federal Police

Funding bodyAustralian Federal Police
Project TeamProfessor Adam McCluskey, Associate Professor Michael Bowyer, Doctor Clovia Holdsworth, Professor Christopher Lennard
SchemeLinkage Projects Partner funding
RoleLead
Funding Start2007
Funding Finish2007
GNoG0187330
Type Of FundingOther Public Sector - Commonwealth
Category2OPC
UONY

Selective Detection and Removal of Organochlorine Residues via MIPs$105,000

Funding body: Entech Industries Pty Ltd

Funding bodyEntech Industries Pty Ltd
Project TeamProfessor Adam McCluskey, Doctor Clovia Holdsworth, Associate Professor Michael Bowyer
SchemePostgraduate Research Scholarship
RoleLead
Funding Start2007
Funding Finish2007
GNoG0187721
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Selective Detection and Removal of Organochlorine Residues via MIPs$105,000

Funding body: Entech Industries Pty Ltd

Funding bodyEntech Industries Pty Ltd
Project Team
SchemeIndustry
RoleLead
Funding Start2007
Funding Finish2007
GNo
Type Of FundingExternal
CategoryEXTE
UONY

20064 grants / $789,182

PRC - Priority Research Centre for Organic Electronics & OrganoBiosensors$549,282

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Paul Dastoor, Professor Adam McCluskey, Professor Erica Wanless, Professor Scott Donne, Doctor John Holdsworth
SchemePriority Research Centre
RoleInvestigator
Funding Start2006
Funding Finish2006
GNoG0186946
Type Of FundingInternal
CategoryINTE
UONY

Consequences of Dynamin 2 PH Domain Dysfunction in Charcot-Marie-Tooth Neuropathy$217,500

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamProfessor Adam McCluskey
SchemeProject Grant
RoleLead
Funding Start2006
Funding Finish2006
GNoG0186208
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Chemical Interventions in Neurological Diseases?$20,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Adam McCluskey
SchemeNear Miss Grant
RoleLead
Funding Start2006
Funding Finish2006
GNoG0186050
Type Of FundingInternal
CategoryINTE
UONY

BIT's 4th Annual Congress of International Drug Discovery Science & Technology 25 May - 2 June 2006$2,400

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Adam McCluskey
SchemeTravel Grant
RoleLead
Funding Start2006
Funding Finish2006
GNoG0186202
Type Of FundingInternal
CategoryINTE
UONY

20051 grants / $207,189

20048 grants / $695,039

Selective detection and removal of contaminants that have an adverse impact on Australian raw sugar quality$190,000

Funding body: ARC (Australian Research Council)

Funding bodyARC (Australian Research Council)
Project TeamProfessor Adam McCluskey, Associate Professor Michael Bowyer, Dr M O'Shea
SchemeLinkage Projects
RoleLead
Funding Start2004
Funding Finish2004
GNoG0183626
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Biacore3000-Expansion of Proteomics Facility$187,341

Funding body: ARC (Australian Research Council)

Funding bodyARC (Australian Research Council)
Project TeamProfessor Alistair Sim, Laureate Professor John Aitken, Emeritus Professor Peter Dunkley, Emeritus Professor John Rostas, Associate Professor Phillip Dickson, Emeritus Professor Leonie Ashman, Professor Roger Smith, Professor Gordon Burns, Professor Adam McCluskey, Associate Professor Paul Tooney, Dr Fraser Ross, Conjoint Professor Ray Rose
SchemeLinkage Infrastructure Equipment & Facilities (LIEF)
RoleInvestigator
Funding Start2004
Funding Finish2004
GNoG0183030
Type Of FundingScheme excluded from IGS
CategoryEXCL
UONY

In-field sensors for the detection of illicit drugs$171,336

Funding body: ARC (Australian Research Council)

Funding bodyARC (Australian Research Council)
Project TeamProfessor Adam McCluskey, Associate Professor Michael Bowyer
SchemeLinkage Projects
RoleLead
Funding Start2004
Funding Finish2004
GNoG0184254
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Selective detection and removal of contaminants that have adverse impact on Australian raw sugar quality$51,000

Funding body: Bureau of Sugar Experiment Stations

Funding bodyBureau of Sugar Experiment Stations
Project TeamProfessor Adam McCluskey, Associate Professor Michael Bowyer
SchemeLinkage Projects Partner funding
RoleLead
Funding Start2004
Funding Finish2004
GNoG0184030
Type Of FundingNot Known
CategoryUNKN
UONY

In-field sensors for the detection of illicit drugs$45,000

Funding body: Australian Federal Police

Funding bodyAustralian Federal Police
Project TeamProfessor Adam McCluskey, Associate Professor Michael Bowyer
SchemeLinkage Projects Partner funding
RoleLead
Funding Start2004
Funding Finish2004
GNoG0185067
Type Of FundingNot Known
CategoryUNKN
UONY

Improving Drug Development: New Approaches to Rapid Development of Novel Lead Compounds$27,542

Funding body: Ramaciotti Foundations

Funding bodyRamaciotti Foundations
Project TeamProfessor Adam McCluskey
SchemeMajor Equipment Award
RoleLead
Funding Start2004
Funding Finish2004
GNoG0183187
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

New drugs targeting protein kinases$17,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamEmeritus Professor Leonie Ashman, Professor Adam McCluskey
SchemeResearch Grant
RoleInvestigator
Funding Start2004
Funding Finish2004
GNoG0183751
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

Radiocarbon dating of heroin samples as a tool to verify the conversion to alternative crops.$5,820

Funding body: AINSE (Australian Institute of Nuclear Science & Engineering)

Funding bodyAINSE (Australian Institute of Nuclear Science & Engineering)
Project TeamProfessor Adam McCluskey
SchemeUse of Facilities Only
RoleLead
Funding Start2004
Funding Finish2004
GNoG0183703
Type Of FundingScheme excluded from IGS
CategoryEXCL
UONY

20034 grants / $475,309

Implementation of a Methamphetamine Method for the Australian Federal Police$230,309

Funding body: Australian Federal Police

Funding bodyAustralian Federal Police
Project TeamProfessor Adam McCluskey
SchemeResearch Grant
RoleLead
Funding Start2003
Funding Finish2003
GNoG0184304
Type Of FundingOther Public Sector - Commonwealth
Category2OPC
UONY

Dynamin inhibitors as tools for dissecting the endocytic pathways neurons$165,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamProfessor Adam McCluskey
SchemeProject Grant
RoleLead
Funding Start2003
Funding Finish2003
GNoG0182859
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

High Pressure and Fluorous Approaches to fostriecin libraries: New Therapeutic Opportunities.$50,000

Funding body: ARC (Australian Research Council)

Funding bodyARC (Australian Research Council)
Project TeamProfessor Adam McCluskey, Assoc. Prof David Young, Doctor Jennette Sakoff
SchemeDiscovery Projects
RoleLead
Funding Start2003
Funding Finish2003
GNoG0182117
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Implementation of a Methamphetamine Method for the Australian Federal Police$30,000

Funding body: Australian Federal Police

Funding bodyAustralian Federal Police
Project TeamProfessor Adam McCluskey
SchemeEquipment Grant
RoleLead
Funding Start2003
Funding Finish2003
GNoG0184303
Type Of FundingOther Public Sector - Commonwealth
Category2OPC
UONY

20024 grants / $598,000

Antagonist of Corticotrophin Releasing Hormone as Therapeutic Agents for the Prevention of Premature Birth in Humans$375,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamProfessor Adam McCluskey, Dr P Keller, Professor Roger Smith, Dr A Ruhmann
SchemeProject Grant
RoleLead
Funding Start2002
Funding Finish2002
GNoG0180905
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Devevelopement and Use of Ionic Liquids in Metal Recovery from Ores, Concentrates and Mattes.$205,000

Funding body: ARC (Australian Research Council)

Funding bodyARC (Australian Research Council)
Project TeamEmeritus Professor Geoffrey Lawrance, Dr I Hamilton, Professor Adam McCluskey
SchemeDiscovery Projects
RoleInvestigator
Funding Start2002
Funding Finish2002
GNoG0181087
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

New targets for chemotherapy: anti-cancer drugs that target protein phosphatases$10,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Adam McCluskey, Conjoint Professor Stephen Ackland, Doctor Jennette Sakoff
SchemeProject Grant
RoleLead
Funding Start2002
Funding Finish2002
GNoG0181459
Type Of FundingInternal
CategoryINTE
UONY

Development of new therapeutic agents for the treatment of epilepsy$8,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Adam McCluskey
SchemeProject Grant
RoleLead
Funding Start2002
Funding Finish2002
GNoG0181460
Type Of FundingInternal
CategoryINTE
UONY

20014 grants / $47,668

Selective detection of Trichloroanisole and other flavour contaminants in wines using molecularly imprinted polymer technology.$30,268

Funding body: Grape & Wine Research and Development Corporation

Funding bodyGrape & Wine Research and Development Corporation
Project TeamProfessor Adam McCluskey
SchemeProject Grant
RoleLead
Funding Start2001
Funding Finish2001
GNoG0181473
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Development of new drugs for the prevention of premature birth$10,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Adam McCluskey
SchemeProject Grant
RoleLead
Funding Start2001
Funding Finish2001
GNoG0180062
Type Of FundingInternal
CategoryINTE
UONY

Environmentally friendly ('Green') organic chemistry: Development of novel methodologies and reagents.$5,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Adam McCluskey
SchemeProject Grant
RoleLead
Funding Start2001
Funding Finish2001
GNoG0180014
Type Of FundingInternal
CategoryINTE
UONY

92nd American Association for Cancer Research Annual Meeting, USA 24-28 March 2001$2,400

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Adam McCluskey
SchemeTravel Grant
RoleLead
Funding Start2001
Funding Finish2001
GNoG0180691
Type Of FundingInternal
CategoryINTE
UONY

20003 grants / $43,950

Selective detection of Trichloroanisole and other flavour contaminants in wines using molecularly imprinted polymer technology.$26,950

Funding body: Grape & Wine Research and Development Corporation

Funding bodyGrape & Wine Research and Development Corporation
Project TeamProfessor Adam McCluskey, Associate Professor Michael Bowyer
SchemeProject Grant
RoleLead
Funding Start2000
Funding Finish2000
GNoG0180158
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Synthesis of Drugs for Prevention of Pre-Term Delivery.$10,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Adam McCluskey, Professor Roger Smith
SchemeProject Grant
RoleLead
Funding Start2000
Funding Finish2000
GNoG0178828
Type Of FundingInternal
CategoryINTE
UONY

Towards Green Chemistry: The Development of Environmentally Organic Synthesis.$7,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Adam McCluskey
SchemeProject Grant
RoleLead
Funding Start2000
Funding Finish2000
GNoG0178827
Type Of FundingInternal
CategoryINTE
UONY

19995 grants / $78,500

Selective Inhibitors of Protein Phosphatases as Anti-cancer agents$25,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Jennette Sakoff, Professor Adam McCluskey, Conjoint Professor Stephen Ackland
SchemeResearch Grant
RoleInvestigator
Funding Start1999
Funding Finish1999
GNoG0178390
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

Selective detection of Trichloroanisole and other flavour contaminants in wines using molecularly imprinted polymer technology$20,000

Funding body: Grape & Wine Research and Development Corporation

Funding bodyGrape & Wine Research and Development Corporation
Project TeamProfessor Adam McCluskey, Associate Professor Michael Bowyer
SchemeProject Grant
RoleLead
Funding Start1999
Funding Finish1999
GNoG0178612
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Rapid Microscale Synthesis of Drugs for the Prevention of Pre-Term Delivery$13,500

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Adam McCluskey, Professor Roger Smith
SchemeProject Grant
RoleLead
Funding Start1999
Funding Finish1999
GNoG0178022
Type Of FundingInternal
CategoryINTE
UONY

Development of a Versatile, Sensitive, Non-Isotopoic Method for Detecting Phosphorylated and Glycosylated Serines in Proteins and Peptides$10,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamEmeritus Professor John Rostas, Professor Adam McCluskey
SchemeCollaborative Research Grant
RoleInvestigator
Funding Start1999
Funding Finish1999
GNoG0178350
Type Of FundingInternal
CategoryINTE
UONY

RMC Collab Partner.Development of a Versatile, Sensitive, Non-Isotopic Method for Detecting Phosphorylated and Glucosylated Serines in Proteins & Peptides.$10,000

Funding body: Bio-Rad Laboratories Pty Ltd (Australia)

Funding bodyBio-Rad Laboratories Pty Ltd (Australia)
Project TeamEmeritus Professor John Rostas, Professor Adam McCluskey
SchemeResearch Grant
RoleInvestigator
Funding Start1999
Funding Finish1999
GNoG0178764
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

19983 grants / $59,164

Low molecular weight ligands for corticotrophin releasing hormone receptors: Drugs for intervention during human pregnancy$47,664

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Adam McCluskey, Dr P Keller, Professor Roger Smith
SchemeSpecial Scholarship Initiative Grants
RoleLead
Funding Start1998
Funding Finish1998
GNoG0177742
Type Of FundingInternal
CategoryINTE
UONY

Computer Modelling and Graphical Representation of the Three Dimensional Structure of Protein Phosphatases$9,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Adam McCluskey
SchemeProject Grant
RoleLead
Funding Start1998
Funding Finish1998
GNoG0177303
Type Of FundingInternal
CategoryINTE
UONY

XVth EFMC International Symposium on Medicinal Chemistry, Scotland 6-10 September 1998$2,500

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Adam McCluskey
SchemeTravel Grant
RoleLead
Funding Start1998
Funding Finish1998
GNoG0180347
Type Of FundingInternal
CategoryINTE
UONY

19973 grants / $38,000

Computer Asisted Design and Chemical Synthesis of Novel Therapeutic Agents Affecting Pregnancy the Duration of Human Pregnancy$16,000

Funding body: ARC (Australian Research Council)

Funding bodyARC (Australian Research Council)
Project TeamProfessor Roger Smith, Professor Adam McCluskey, Professor Alan Boura
SchemeSmall Grant
RoleInvestigator
Funding Start1997
Funding Finish1997
GNoG0176726
Type Of FundingScheme excluded from IGS
CategoryEXCL
UONY

Design and Synthesis of Novel Corticotropin-Releasing Hormone Receptors Agaonists/Antagonists: Development of New Therapeutic Agents$15,000

Funding body: Ramaciotti Foundations

Funding bodyRamaciotti Foundations
Project TeamProfessor Adam McCluskey, Ian Leitch
SchemeResearch Grant
RoleLead
Funding Start1997
Funding Finish1997
GNoG0176500
Type Of FundingAust Competitive - Non Commonwealth
Category1NS
UONY

Development Of A Novel, Photolytic Oxidising Agent For Use In Synthetic Chemistry.$7,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Adam McCluskey
SchemeProject Grant
RoleLead
Funding Start1997
Funding Finish1997
GNoG0176634
Type Of FundingInternal
CategoryINTE
UONY

19961 grants / $12,500

Design & Synthesis ofNovel Protein Phosphatase 1 & Protein Phosphatase 2A Inhibitors$12,500

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Adam McCluskey
SchemeNew Staff Grant
RoleLead
Funding Start1996
Funding Finish1996
GNoG0176326
Type Of FundingInternal
CategoryINTE
UONY
Edit

Research Supervision

Current Supervision

CommencedResearch Title / Program / Supervisor Type
2015Applications of Flow Chemistry to the Synthesis of Novel Classes of Iminosugars
Chemical Sciences, Faculty of Science and Information Technology
Co-Supervisor
2015Applications of Flow Chemistry to the Synthesis of Novel Classes of Iminosugars
Chemical Sciences, Faculty of Science and Information Technology
Co-Supervisor
2015Applications of Flow Chemistry to the Synthesis of Novel Classes of Iminosugars
Chemical Sciences, Faculty of Science and Information Technology
Co-Supervisor
2014Novel Classes of Iminosugars as Glycosidase Inhibitors via a Flow Chemistry Approach
Chemical Sciences, Faculty of Science and Information Technology
Co-Supervisor
2013Pathogenic Retroviruses - Developing Next Generation Antiviral Agents
Chemical Sciences, Faculty of Science and Information Technology
Principal Supervisor
2013Genetic Consequences of Paternal Acrylamide Exposure and Potential for Amelioration
Biological Sciences, Faculty of Science and Information Technology
Co-Supervisor
2012Hedgehog Signaling Pathway Inhibitors as Cancer Suppressing Agents
Biological Sciences, Faculty of Science and Information Technology
Principal Supervisor
2011The Development of Flow Chemistry Methodologies for the Synthesis of Potential Anti-Cancer Agents
Chemical Sciences, Faculty of Science and Information Technology
Principal Supervisor
2011Synthesis of Bolinaquinone Analogues as Clathrin Inhibitors
Chemical Sciences, Faculty of Science and Information Technology
Principal Supervisor
2010Application of Green Chemistry Approaches to the Ugi and Passerini Multicomponent Reactions
Chemical Sciences, Faculty of Science and Information Technology
Principal Supervisor
2010The Characterisation and Classification of Residual Tool Marks on Bone Inflicted by Machetes and Samurai Swords (Sharp and Blunt) and the Survivability of Those Marks Following Thermal Trauma (Fire).
General Medicine, Faculty of Health and Medicine
Co-Supervisor
2006Novel Inhibitors of Dynamin GTPase
Chemical Sciences, Faculty of Science and Information Technology
Sole Supervisor

Past Supervision

YearResearch Title / Program / Supervisor Type
2014Exploring Signal Transduction Mechanisms in Molecularly Imprinted Polymers for Forensic Applications
Chemical Sciences, Faculty of Science and Information Technology
Co-Supervisor
2014Drugs from Nature: 1. Dynamin I Inhibitors from Mexican Marine Algae; 2. Chemical Investigation of an Australian Aboriginal Traditional Remedy
Chemical Sciences, Faculty of Science and Information Technology
Co-Supervisor
2013Design and Synthesis of Molecularly Imprinted Polymers for the Selective Extraction of Polychlorinated Biphenyls
Chemical Sciences, Faculty of Science and Information Technology
Principal Supervisor
2013Synthesis and Evaluation of Norcantharidin and Acrylonitrile Derivatives as Potential Anti-Cancer Agents
Chemical Sciences, Faculty of Science and Information Technology
Principal Supervisor
2013A Mechanistic Study into the Reaction Between Carbon Dioxide and Amines
Chemical Sciences, Faculty of Science and Information Technology
Principal Supervisor
20121. Dynamin-l Inhibitors from Sessile Marine Invertebrates; 2. Chemotaxonomy of Cystophora spp.
Chemical Sciences, Faculty of Science and Information Technology
Principal Supervisor
2012Disruption of Clathrin Mediated-Endocytosis through Small Molecule Inhibition of Dynamin and Clathrin
Chemical Sciences, Faculty of Science and Information Technology
Principal Supervisor
2012Synthesis, Characterisation and Evaluation of Biphenyl Monomers for Molecular Imprinting Applications
Chemical Sciences, Faculty of Science and Information Technology
Principal Supervisor
2011Novel Inhibitors of Clathrin Mediated Endocytosis
Chemical Sciences, Faculty of Science and Information Technology
Principal Supervisor
2010Towards the Development of a Benzylpiperazine Specific Molecular Imprinted Polymer
Chemical Sciences, Faculty of Science and Information Technology
Co-Supervisor
2010Optimisation of Molecularly Imprinted Polymeric Films for the Detection of L-Ephedrine
Chemical Sciences, Faculty of Science and Information Technology
Principal Supervisor
2010Characterisation and Improved Performance of Molecularly Imprinted Polymers Prepared Using Room Temperature Ionic Liquids
Chemical Sciences, Faculty of Science and Information Technology
Co-Supervisor
2009Norcantharidin Analogues: PP1 and PP2A Inhibition and Potential Therapeutic Development
Chemical Sciences, Faculty of Science and Information Technology
Principal Supervisor
2008Ionic Liquids for Synthesis and Metal Recovery
Chemical Sciences, Faculty of Science and Information Technology
Co-Supervisor
2008Design and Synthesis of Molecularly Imprinted Polymers for the Selective Recognition of Small Chloro-Arene Contaminants
Chemical Sciences, Faculty of Science and Information Technology
Principal Supervisor
2007Design and Synthesis of Novel Dynamin GTPase Inhibitors
Chemical Sciences, Faculty of Science and Information Technology
Sole Supervisor
2006Cantharidin Analogues: Potential Therapeutic Agents
Chemical Sciences, Faculty of Science and Information Technology
Sole Supervisor
2006Ionic Liquids for Explosive Technologies
Chemical Sciences, Faculty of Science and Information Technology
Co-Supervisor
2006Novel Inhibitors of Dynamin GTPase
Chemical Sciences, Faculty of Science and Information Technology
Sole Supervisor
2006New Routes To Precious Metal Recovery Using Ionic Liquids
Chemical Sciences, Faculty of Science and Information Technology
Co-Supervisor
2005Chemotaxonomy of the brown algal genus Cyclophoria
Chemical Sciences, Faculty of Science and Information Technology
Co-Supervisor
2004Design and Synthesis of Potential CRHR1 Antagonists
Chemical Sciences, Faculty of Science and Information Technology
Sole Supervisor
2004Development Towards Structurally Unprecedented Corticotropin Releasing Hormone Type-1 Receptor Antagonists
Chemical Sciences, Faculty of Science and Information Technology
Sole Supervisor
Edit

News

ERA Research Evaluation Committees 2015

ERA Research Evaluation Committees 2015

February 20, 2015

Nine University of Newcastle researchers have been selected by the Australian Research Council for membership of the 2015 Excellence in Research for Australia (ERA) Research Evaluation Committees.

Smoking and male fertility breakthrough finding

October 1, 2014

Mothers who smoke while they are pregnant or breast feeding may be damaging the future fertility of their sons, according to breakthrough findings from University of Newcastle researchers published today.

Professor Adam McCluskey

Position

Professor
School of Environmental and Life Sciences
Faculty of Science and Information Technology

Focus area

Chemistry

Contact Details

Emailadam.mccluskey@newcastle.edu.au
Phone(02) 4921 6486
Fax(02) 4921 5472

Office

RoomC318
BuildingChemistry
LocationCallaghan
University Drive
Callaghan, NSW 2308
Australia
Edit